欧州 Europe – ページ 14 – ワールドソルーションズLLC

#Coronavirus #コロナウイルス Vol.20（vaccines ワクチン）／ U.S.A. アメリカ Vol.130（Massachusetts マサチューセッツ州 Vol.4 / New York ニューヨーク州 Vol.5: pharmaceutical corporations 製薬会社 – Moderna モデルナ社、Pfizer ファイザー社）

All the below links, excerpts, and tweets are in English.

cf. #Coronavirus #コロナウイルス Vol.19（vaccines ワクチン）／ U.S.A. アメリカ Vol.129（New York ニューヨーク州 Vol.4 / Massachusetts マサチューセッツ州 Vol.3: pharmaceutical corporations 製薬会社 – Pfizer ファイザー社、Moderna モデルナ社）

昨日に引き続き取り急ぎ以下貼っておきます。

Multidose COVID-19 vaccines will test state tracking systems: People have to get two shots of the same type of vaccine (12/04/2020) | @verge
… Both take two doses, given a few weeks apart, and both could be circulating at the same time. And that’s just the two front-runners. Other multidose vaccines are still in the development pipeline.
There are a few ways states, doctors, and patients could keep the dosages straight, says Claire Hannan, executive director of the Association of Immunization Managers. In the simplest solution, everyone who gets a COVID-19 vaccine will also get a card that tells them which vaccine they had and when their next dose should be. But that’s the last line of defense in a complex vaccine tracking system. “As the backup to the backup to the backup, they’ll hand out cards,” Hannan says.
Ideally, the cards won’t be necessary because patients and doctors will be able to rely on electronic records and digital registry systems to keep track of who got which vaccine and when they got it. Through the pandemic, states have struggled with digital systems for other key areas, like COVID-19 testing – sometimes relying on fax machines and incomplete, handwritten forms to send information from testing sites to local health departments. But Hannan says the US immunization data collection systems at the state level are prepared to manage the expected crush of information from an unprecedented mass vaccination campaign like the one the country is about to start. Most tools were in place even before the pandemic hit. …
Big health systems with robust electronic health record management will likely have an easier time with this process than smaller clinics, says Howard Forman, a professor of public health, management, and economics at Yale University. “They’re used to keeping track of whether patients have had their followup appointments…
… Each state has its own Immunization Information System (IIS), a centralized registry that keeps track of every vaccine each person vaccinated in that state has received. Vaccination clinic software and electronic health records systems feed into those registries, which help doctors keep track of the vaccination records for individual patients, and also give each state big-picture data on vaccination rates in individual communities.
A state-level IIS can also notify doctors and patients when people are due for a second dose of a vaccine. They already use them to keep track of doses for the meningitis B vaccine…
The systems in place to track vaccinations today are much more advanced than they were in 2009, when the country struggled to distribute and track the H1N1 flu vaccine (which was only one shot), and electronic health records were rare. Only some states used their IIS programs. Many states had to rely on SurveyMonkey to connect with health care providers about vaccine delivery…

Moderna reaffirms 20M vaccine dose goal for December (12/04/2020) | @BosBizJournal
… The biotech has enlisted Italian firm Lonza to ramp up production to 500 million to one billion doses of the vaccine annually and Catalent Inc. to make all of the labels, seals and glass vials. Local life sciences unicorn Ginkgo Bioworks has also been helping Moderna optimize its production of raw materials for the drug.
Moderna has additionally hired another 150 employees to produce the vaccine out of its Norwood manufacturing facility. …

Moderna says its vaccine candidate has ‘potential’ to confer longer-term immunity (12/03/2020) | @MarketWatch
…National Institute of Allergy and Infectious Diseases…
The company said it remained confident it will have 20 million doses of the vaccine candidate available in the U.S. by the end of the year, and it expects to have between 100 million and 125 million doses available globally in the first quarter of next year.
Of these, between 85 million and 100 million will be available in the U.S. and between 15 million and 25 million will be available elsewhere…

Moderna’s 3-month data raise hopes for COVID-19 vaccine durability (12/04/2020) | @FierceBiotech
… Moderna shared details of the NEJM letter alongside an update on its effort to scale up production. …
Moderna Provides Updates on the Clinical Development and Production of Its COVID-19 Vaccine Candidate (12/03/2020) | @moderna_tx
… “mRNA-1273 produced high levels of binding and neutralizing antibodies that declined slightly over time, as expected, but they remained elevated in all participants three months after the booster vaccination.”…
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination (12/03/2020) | @NEJM

What it feels like to get Moderna’s COVID-19 vaccine: “It’s not pleasant, but it’s definitely worth the risk of developing these side effects to make sure we can find an end to this pandemic.” (12/03/2020) | @BostonDotCom
Saginaw doctor who took part in Moderna vaccine trial seeks to reassure public (12/04/2020) | @MLive
Moderna Says COVID Vaccine Could Create Immunity For At Least Three Months (w Video; 12/04/2020) | @wbz
New data shows people who got Moderna vaccine still had antibodies 3 months later: The data came from a small number of phase 1 participants. (04/12/2020) | @ABCNews
Continuing COVID-19 vaccine trials may put some volunteers at unnecessary risk. Is that ethical? (w Video; 12/04/2020) | @USATODAY
No legal grounds for employers to force employees to get vaccinated, say experts (12/04/2020) | @CTVNews

Canada doubles Moderna vaccine order, daily COVID-19 cases could top 10,000 by January (12/04/2020) | @reuters
… Anand also said FedEx Corp and Innomar Strategies, a Canada-based division of AmerisourceBergen, had been contracted by the federal government to provide logistical support on vaccine delivery.

Moderna COVID vaccine best for Nunavut because of storage, shipping: top doctor (12/04/2020) | @CKOMNews
… Moderna’s vaccine is preferred because the Pfizer one requires cold storage and shipping would be too difficult in Nunavut. …

Two vaccines might get emergency approval this month. Here’s what you need to know (12/01/2020) | @latimes
What about those second doses?
The CDC’s vaccine tracking system will monitor who gets a first dose and will coordinate with Pfizer and Moderna on the shipment of the second doses. This means medical centers can administer all the doses they initially receive without having to hold onto half for the second shot.
How long before I can drive to my local pharmacy and get a vaccine?
If you’re healthy and a nonessential worker, you will have to wait. Most experts feel that the immunization effort in the United States will be in high gear by late spring and early summer of 2021…

Moderna to submit Covid-19 vaccine to FDA as full results show 94% efficacy (11/30/2020) | @statnews
… Moderna said that safety data is being reviewed continuously, but that there are no new serious safety concerns. The most common adverse events included site pain, fatigue, muscle or bone pain, headaches, and redness at the injection site. The reactions were more serious in the vaccine group after patients received a second dose. The results Pfizer and BioNTech released 12 days ago for their vaccine are roughly similar. …
… Each strand of synthetic mRNA is designed to encode for a protein found on the surface of SARS-CoV-2, the virus that causes Covid-19. Those mRNA strands enter the body’s cells and instruct them to produce that protein. The immune system then recognizes it as a foreign invader and produces antibodies that protect against Covid-19 if a person is later exposed to the virus.
The Covid-19 vaccine would be Moderna’s first product approved by the FDA and, assuming Pfizer’s vaccine is approved first, only the second mRNA medicine ever licensed. …

Moderna’s COVID-19 Vaccine Candidate Gets More Good News (w Voice; 11/30/2020) | @NPR
… Both use the same novel technology. Instead of injecting a weakened or dead virus, which is a common strategy for vaccines, these products are essentially small pieces of genetic material. When that’s injected into a person’s arm, it’s picked up by cells in the immune system. The cells read the genetic code and use that to produce a protein that is actually a key fragment of the coronavirus. The body then builds antibodies that latch onto that fragment, so if and when someone encounters the actual coronavirus, the body is primed to fight it off with antibodies. …

Could the FDA have moved even faster to review Covid-19 vaccines? @NicholasFlorko and I take a look.$PFE $BNTX $MRNA https://t.co/DTvlS3tcMd

— Matthew Herper (@matthewherper) December 4, 2020

We are expanding our particle engineering & drug product capabilities in our Bend (OR) site to support our partners' early-phase programs. Our investment will bring 11 new suites to improve program lead times. #SmallMolecules https://t.co/xIGdCMLeL4 pic.twitter.com/oDwtO2csY5

— Lonza Pharma & Biotech (@LonzaPB) December 3, 2020

#COVID19 is requiring a significant reduction in development & clinical trial timelines. Catalent Biologics’ Mike Riley addresses manufacturing challenges & discusses how collaborative partnerships are crucial. https://t.co/UE8ND6fssL

— Catalent Pharma (@CatalentPharma) December 3, 2020

COVID-19 is the greatest biological crisis of our generation. We are honored to be able to contribute our technology to efforts combating the pandemic and grateful for the support from the @DFCgov to expand our biosecurity platform. https://t.co/83sqXw5jtr

— Ginkgo (@Ginkgo) November 25, 2020

Our Chairman, President and CEO, Steve Collis, spoke with @thehill’s Steve Clemons about leveraging the #pharma #supplychain’s expertise during the ongoing #COVID pandemic. Watch here: https://t.co/nftGq06oaf

— AmerisourceBergen (@Healthcare_ABC) December 4, 2020

The executive director of the Association of Immunization Managers said states have not been given a date to expect shipments of coronavirus vaccines, but they’re preparing to receive them as early as December 11. https://t.co/bTkrFLNc95

— KEYT NewsChannel 3 (@KEYTNC3) December 1, 2020

The COVID-19 vaccine should go ‘into arms’ not ‘into storage’: Association of Immunization Managers Director https://t.co/t9tCBPfVQx via @Yahoo

— Raymond Gibbs (@raygibbs1) December 2, 2020

Dr. Mena Khan, assistant director of medical simulation at the Covenant HealthCare Simulation Center at @CMU_Medicine in Saginaw, reflected on her experience participating in phase three of the Moderna #COVID19Vaccine trial. Read more: https://t.co/fBc6H8kkcq @CMUniversity

— CMU Health (@CMU_Health) December 4, 2020

#Coronavirus #コロナウイルス Vol.19（vaccines ワクチン）／ U.S.A. アメリカ Vol.129（New York ニューヨーク州 Vol.4 / Massachusetts マサチューセッツ州 Vol.3: pharmaceutical corporations 製薬会社 – Pfizer ファイザー社、Moderna モデルナ社）

All the below links, excerpts, and tweets are in English.
cf.
U.S.A. アメリカ Vol.107（New York ニューヨーク州 Vol.2: pharmaceutical corporations 製薬会社）
U.S.A. アメリカ Vol.113（Massachusetts マサチューセッツ州 Vol.2: pharmaceutical corporations 製薬会社）

取り急ぎ以下貼っておきます。

Pfizer And Moderna Face Their Biggest Challenge: Vaccinating The World (12/03/2020) | @IBDinvestors
… The obstacles can’t be overestimated, experts say. The vaccine supply chain is mindbogglingly complex. It involves local, state and federal authorities as well as hospitals, pharmacies and doctors’ offices.
The two most advanced coronavirus vaccines must be stored at specific temperatures and given in two doses several weeks apart. Stakeholders must keep tabs on who gets which vaccine and when. And don’t forget the public perception challenges of vaccinating people with drugs that went through clinical testing at record speeds.
Experts say 60% to 80% of the world must be vaccinated to achieve herd immunity. It will be many months – or years – before that happens as vaccine makers iron out supply constraints. Besides the Covid-19 vaccine companies themselves, a raft of other parties like drug distribution company McKesson (MCK) will be involved.
…the Centers for Disease Control and Prevention. The agency has overseen vaccine distribution in the U.S. for decades, including the national effort to vaccinate during the H1N1 influenza pandemic in 2009.
The coronavirus vaccination effort will probably look similar to that…
First, vaccination sites will need to enroll in the CDC’s Covid-19 vaccine distribution program. These sites will include doctors’ offices, clinics, hospitals and pharmacies. The program ensures these locations have enough well-trained staff, the right equipment and space to vaccinate large numbers of people.
Then, the vaccination sites will request doses of the coronavirus vaccine through a state agency…
Public health officials will then confirm the vaccination site is approved. If so, the order will head to the CDC. …
In August, the CDC tapped McKesson to help it distribute all coronavirus vaccines. …McKesson could rely on UPS, DHL and FedEx trucks to help it get the job done.
Pfizer, on the other hand, has a bigger challenge. The company’s coronavirus vaccine must be stored at ultracold temperatures. How cold? Penguins would find these temperatures chilly. …
Moderna’s vaccine can live in a standard refrigerator for 30 days. It can also be frozen for six months. Once thawed, providers must administer the vaccine within 12 hours – or toss it out. That creates a logistical challenge for transportation.
“Moderna will be heavily reliant on external suppliers…It will be using companies like CryoPort (CYRX), Stirling Ultracold and CH Robinson (CHRW) to work out cold chain logistics plus storage and shipping management.” …
…Pfizer has developed a special shipping container that can store the coronavirus vaccine for 10 days unopened…
The vaccine can be stored in an ultracold freezer for up to six months. It can stay in the shipping container for up to 30 days when replenished with dry ice every five days. Or, the drug can be stored for five days in a standard refrigerator.
…the strict storage requirements limit where Pfizer’s vaccine can be used. Those ultracold freezers cost about $20,000 apiece. …
…”Imagine getting one dose to Appalachia, a rural community. Now imagine having to come back and making sure everyone who got the first dose also gets the second one. That’s a challenge.”
…it’s likely the Pfizer vaccine will go to more populous locations with cold-storage capabilities. Coronavirus vaccine stock Moderna will probably send its drug to more rural communities.
…expects Pfizer to generate $875 million in coronavirus vaccine sales in 2020 and $7.25 billion in 2021. Eventually, that will trend down to $700 million to $800 million each year, depending on how often people need booster shots of the vaccine. …
“The drugmaker that gets this thing out first…Overnight, Pfizer becomes one of the most loved brands in America. It’s the McDonald’s (MCD) of the pharma industry.”

Pfizer to Ship Half as Many Coronavirus Vaccine Doses as Originally Planned in Initial Phase (12/03/2020) | @themotleyfool
…”Scaling up the raw material supply chain took longer than expected, and it’s important to highlight that the outcome of the clinical trial was somewhat later than the initial projection.”
BNT162b2, which showed an extremely high efficacy rate of 95% with no serious safety concerns in phase 3 clinical trials, has been submitted for similar approvals throughout the European Union, and with the U.S. Food and Drug Administration (FDA). In the wake of the U.K. approval, Pfizer and BioNTech anticipate decisions from other major regulators this month. …

Pfizer Scaled Back Vaccine Output Targets Earlier This Year (12/03/2020) | @business
…supply-chain problems caused the New York-based drugmaker to reduce the number of vaccines…led Pfizer shares to fall as much as 3.1% and caused the wider stock market to dip. The S&P 500 ended Thursday’s trading down 0.1%. …
Moderna Inc., which has also submitted a messenger RNA-based vaccine to the FDA for emergency clearance, said in a statement on Thursday it would have between 100 million and 125 million doses available globally in the first quarter of 2021. …

UK becomes the first to approve Pfizer-BioNTech Covid vaccine, rollout due next week (12/02/2020) | @CNBC
…with elderly people in care homes and medical workers first in line. …
“The government has today accepted the recommendation from the independent Medicines and Healthcare products Regulatory Agency (MHRA)…
Pfizer and BioNTech announced in July an agreement with the U.K. to supply 30 million doses of its mRNA-based vaccine…increased to 40 million doses in early October. As a two-dose vaccine, the U.K. will have enough doses to vaccinate around a third of its 66 million population. …
“I consider this decision to be problematic and recommend that EU Member States do not repeat the process in the same way. A few weeks of thorough examination by the European Medicines Agency is better than a hasty emergency marketing authorization of a vaccine,” said Peter Liese, a member of German Chancellor Angela Merkel’s party…

Pfizer supply chain challenges led to slashing COVID-19 vaccine production target – WSJ (12/03/2020) | @reuters,@YahooFinance
…anticipates producing 50 million doses of its COVID-19 vaccine this year. That is down from an earlier target of 100 million doses. Pfizer’s vaccine relies on a two dose regimen, meaning 50 million doses is enough to inoculate 25 million people. …
David Perdue bought Pfizer stock – a week before company said it would develop a vaccine (12/03/2020) | @salon

$PFE and $MRNA could face several distribution challenges for their #COVID-19 vaccines. Our own @healthtechetf shares her research of this development in @IBD_AGatlin's latest: https://t.co/uVhICfrWaV

— ROBO Global (@ROBOGlobal) December 3, 2020

Jeylan Mammadova, Global Sector Lead at Third Bridge, joins USA Today to discuss the roll out of a #COVID19 vaccine https://t.co/NlyBmbeDLm

— Third Bridge (@teamthirdbridge) December 3, 2020

Clear and somewhat comforting explanation of the complicated supply chain for COVID vaccines. Here's how it will work. By @markfischetti with @jlswann of @NCState on @SciAm https://t.co/auVC5xutq5

— Laura Helmuth (@laurahelmuth) November 19, 2020

ICYMI: Watch on @bloombergTV
— Cryoport, Inc. CEO Jerrell Shelton discusses the logistics and challenges in distributing a COVID-19 vaccine: https://t.co/riVJkj6n5S @markets @business
#COVID19 #CovidVaccine #biopharma #biotech $CYRX

— Cryoport, Inc. (@cryoport) December 2, 2020

Check out Dusty Tenney’s interview on @CNBC’s @SquawkStreet! Our partnership with @UPS_Healthcare was discussed, and how complex supply chains are being built to ensure #COVID-19 vaccines will be stored at the required cold temperatures. #coldchain https://t.co/GfebgXCyWM

— Stirling Ultracold (@StirlingULTra) December 3, 2020

Thanks to @ABC News for highlighting our collaboration with @UPS_Healthcare in this article. We are ramping up production to deliver thousands of our portable ULT25NEU freezers for last mile COVID-19 vaccine distribution and storage. https://t.co/xz1pIgqTPs pic.twitter.com/GC1zJTOuCg

— Stirling Ultracold (@StirlingULTra) December 2, 2020

Safely delivering #COVID-19 vaccines and therapies to developing nations and remote locations is challenging. @Engineering_360 highlights how our ULT25NEU ULT freezer is a portable solution that can maintain the cold chain and support this global effort. https://t.co/9P1SSiYDcz pic.twitter.com/QUVpZOEXp7

— Stirling Ultracold (@StirlingULTra) December 3, 2020

Jeylan Mammadova, Global Sector Lead at Third Bridge, joins USA Today to discuss the roll out of a #COVID19 vaccine https://t.co/NlyBmbeDLm

— Third Bridge (@teamthirdbridge) December 3, 2020

Clear and somewhat comforting explanation of the complicated supply chain for COVID vaccines. Here's how it will work. By @markfischetti with @jlswann of @NCState on @SciAm https://t.co/auVC5xutq5

— Laura Helmuth (@laurahelmuth) November 19, 2020

Science and Technology 科学技術 Vol.14 ／ #Coronavirus #コロナウイルス Vol.15（pharmaceutical products 医薬品 Vol.6：drugs 治療薬）

All the below links and excerpts are in English.

Tocilizumab/Atlizumab（Actemra®）に係るリンクと当方作成の抜粋を取り急ぎ以下のとおり貼っておきます。

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial (w PDF; 10/20/2020) | @JAMANetwork
PDF　

Efficacy and safety of tocilizumab in COVID-19 patients: A living systematic review and meta-analysis (w PDF; 11/05/2020) | @CMIJournal
Conclusion
Cumulative moderate certainty evidence shows that tocilizumab reduces the risk of mechanical ventilation in hospitalized COVID-19 patients. While RCTs showed that tocilizumab did not reduce short-term mortality, low certainty evidence from cohort studies suggests an association between tocilizumab and lower mortality. We did not observe a higher risk of infections or adverse events with tocilizumab use. This review will continuously evaluate the role of tocilizumab in COVID-19 treatment.

Efficacy of Tocilizumab on Patients With COVID-19 (08/24/2020) | @MGHMedicine,@genentech ClinicalTrials.gov @nlm_news
Brief Summary:
This is a randomized, double blind, multi-center study to evaluate the effects of tocilizumab compared to placebo on patient outcomes in participants with confirmed SARS-CoV-2 infection and evidence of systemic inflammation.
The aim of this study is to test the effect of Tocilizumab on multi-organ dysfunction in a phase 3 randomized controlled trial among hospitalized patients with COVID-19 infection.
Specifically, as compared to placebo, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory measures. Multi-organ dysfunction will be measured as the incidence of the following composite endpoint (mechanical ventilation, renal replacement therapy, mechanical support, need for inotropes or vasopressors, liver dysfunction (increased bilirubin), and all-cause mortality). We will also assess multiple pre-specified secondary (exploratory) endpoints and safety endpoints.
We hypothesize that, as compared to placebo, tocilizumab will reduce transfer to the ICU, need for mechanical ventilation, increase rates of hospital discharge in patients diagnosed with severe COVID-19 infection and evidence of exaggerated inflammatory response.

New results from a once-promising therapy show the difficulty of treating covid-19: In one study, the drug, tocilizumab, reduced risk of death in ICU patients, but two others found negligible results with slightly different patients (10/21/2020) | @washingtonpost
Studies offer little hope for tocilizumab in treating COVID (10/20/2020) | @CIDRAP
Time to Reassess Tocilizumab’s Role in COVID-19 Pneumonia (10/20/2020) | @JAMANetwork
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 (10/20/2020) | @JAMANetwork

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 (10/21/2020) | @NEJM
Tocilizumab for COVID-19? Three Studies Yield Mixed Findings (10/20/2020) | @JWatch
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (w PDF; 21/10/2020) | Journal of Translational Medicine
Appropriate use of tocilizumab in COVID-19 infection (w PDF; 10/2020) | International Journal of Infectious Diseases @ElsevierConnect
PDF　

Roche’s Actemra helps keep coronavirus patients off ventilators despite earlier trial flop (09/18/2020) | @FiercePharma
…Roche is also pairing Actemra with Gilead Sciences’ antiviral Veklury, better known as remdesivir, in the phase 3 Remdacta trial. Eli Lilly’s JAK arthritis med Olumiant combined with Veklury helped patients recover faster in a recent trial run by the National Institute of Allergy and Infectious Diseases.

Tocilizumab/IL-6 Inhibitors | @RealTimeCOVID19
Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019. | @WHO
Decreased Mortality in Coronavirus Disease 2019 Patients Treated With Tocilizumab: A Rapid Systematic Review and Meta-analysis of Observational Studies (w PDF; 23/09/2020) | @OUPAcademic
Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease (09/16/2020) | @NCBI
Efficacy of tocilizumab in COVID‐19: A systematic review and meta‐analysis (w PDF; 12/09/2020) | @WileyGlobal
Glucocorticoids, tocilizumab may reduce complications in COVID-19-related cytokine storm (09/03/2020) | @HealioRheum
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study (w PDF; 08/14/2020) | @TheLancetRheum
Tocilizumab in patients with severe COVID-19: a retrospective cohort study (w PDF; 08/01/2020) | @TheLancetRheum
Chugai Starts Phase III Clinical Trial of Actemra for COVID-19 Pneumonia in Japan (04/08/2020) | @chugai_cc
What is the role of the IL-6 inhibitor tocilizumab (Actemra) in the treatment of coronavirus disease 2019 (COVID-19)? (11/10/2020) | @Medscape

Australia オーストラリア Vol.10（pharmaceutical corporations 製薬会社）

All the below links and tweets are in English.

取り急ぎ以下貼っておきます。

CSL（豪）の子会社
Pennsylvania Vol.11 (corporations: CSL Behring) / Australia Vol.29
UK Vol.173 (pharmaceutical corporations: Seqirus) / Australia Vol.30

上記リンク内に無い本日までのツイート

CSL #FlashbackFriday – 10 Decades in 10 Weeks
1946 to 1956: CSL is manufacturing polio vaccine, a wide range of human and veterinary vaccines, antisera to some of Australia's most venomous snakes and spiders, insulin, penicillin and a suite of blood products. pic.twitter.com/XXkR5KPiD7

— CSL (@CSL) November 5, 2020

https://twitter.com/SamDForever1/status/1325970911258836992

Coronavirus vaccine production begins in Australia before Oxford-AstraZeneca's products last stage of approval @AstraZeneca @csl #Vaccine #Covid19 #Coronavirus https://t.co/U8zKQWp6QX pic.twitter.com/6J6sHNaypJ

— ProTech Recruitment Ltd (@ProTechLtd) November 9, 2020

.@CSL began manufacturing the University of Oxford/AstraZeneca AZD1222 Covid-19 vaccine candidate at its facility in Broadmeadows in northern Melbourne today.https://t.co/xBb64K7DHA #COVID19 #vaccine #manufacturing

— AustralianManufacturingForum (@AuManufacturing) November 9, 2020

Global #biotech company @CSL has commenced the manufacture of University of Oxford/AstraZeneca Vaccine Candidate in Melbourne – a further endorsement for the city’s thriving biotech and #advancedmanufacturing capabilities https://t.co/vb5JAlVy0F pic.twitter.com/dtHis3oOWm

— Invest Victoria (@InvestVictoria) November 9, 2020

.@CSL commences manufacture of @UniofOxford /@AstraZeneca vaccine candidate: https://t.co/6CjpTf2qNL

— AUS Manufacturing (@AustralianM) November 9, 2020

https://twitter.com/DayofImmunology/status/1325371202831962112

A great example of how videos can assist in communicating share plans to employees by Australian company @CSL #EmployeeOwnership #EmployeeOwned https://t.co/drAi6zwle7

— Employee Ownership Australia (@EOwnership) November 6, 2020

This is quite remarkable: you’re looking at the first vial of ‘starting material’ of the @AstraZeneca COVID-19 vaccine in Australia. @CSL will start making millions of doses from tomorrow – in anticipation of final approvals next year. @7NewsMelbourne pic.twitter.com/UkHzZNrAkF

— Blake Johnson (@BlakeJohnson) November 8, 2020

“The #Australian government… said on Thursday [it] will buy 40M #vaccine doses from @Novavax, and 10 million from @Pfizer and @BioNTech_Group… That adds to the 85M doses Australia has already committed to buy from @AstraZeneca and @CSL…” #COVID19 https://t.co/4pe1y0mEWl

— Mark Warner (@MAAWLAW) November 5, 2020

Morning Bell: #ASX200 to gain 0.2% at the open. VIC #COVID19 restrictions have been eased & @CSL is set to produce 30 mil #COVID19Vaccines. #Brexit talks to dominate this week, keep an eye on $LNK & $VUK. Trading ideas: $MQG & $BXB. #ausbiz #belldirect https://t.co/Qb1Xf7JJlo

— Bell Direct (@belldirect) November 8, 2020

Are you debating your holiday plans? Get some expert advice about how to stay safe, especially if you're living with a rare or chronic illness. https://t.co/5iXQVwsaUC

— CSL Behring (@CSLBehring) November 6, 2020

Help raise awareness this November – it's #Alpha1Awareness month – by learning more. It’s a rare hereditary respiratory condition sometimes called genetic #COPD. It’s estimated only 10% of patients are properly diagnosed…could you be one of them? https://t.co/tndZncDf1n

— CSL Behring (@CSLBehring) November 5, 2020

Scientists at #CSLBehring are offering some advice about how to clean up at home and prevent the spread of #COVID19. They tested several cleaning agents, including a commonly available household soap, and found they all killed the virus. https://t.co/LP7GuI673O

— CSL Behring (@CSLBehring) November 5, 2020

Today, the study design for our landmark Phase 3 AEGIS-II trial was published in @AmericanHeartJ Read more about our cardiovascular research program involving #heartattack survivors: https://t.co/WByn9r3ny6 @CMichaelGibson #cardiotwitter pic.twitter.com/go8GivEfAw

— CSL Behring (@CSLBehring) November 5, 2020

One key lesson from the #COVID19 pandemic is the need for global cooperation to develop potential therapeutics. #CSLBehring is proud to collaborate with our partners in the CoVIg-19 Plasma Alliance on a potential treatment. More here: https://t.co/La5JtJmMkp

— CSL Behring (@CSLBehring) November 2, 2020

#NEWS: Both the @US_FDA and @EMA_News have granted orphan drug designation to our investigational therapy for #SickleCellDisease Learn more: https://t.co/aJ36nNJ1JA @GregoryKatoMD pic.twitter.com/VghvWrIBpB

— CSL Behring (@CSLBehring) November 2, 2020

https://twitter.com/CSLBehring/status/1322931444545703938

CSL Behring Publishes Design for First-Ever Outcomes Study of ApoA-I to Reduce Risk of Cardiovascular Events in Heart Attack Patientshttps://t.co/dcDfXyJNgb @CSLBehring #cardiologist #doctor #cardio #cardiovascular #ECG #HeartNews #healthcare #medicaltechnology

— Cardiology 2.0 (@cardiology_2) November 5, 2020

.@CSLBehring's @johnkthompson60 shares advice on scaling #datascience — making the case for a #COE, building a team from scratch, setting priorities, and more: https://t.co/o5ivCh9qox pic.twitter.com/a49gANEJiA

— Domino Data Lab (@DominoDataLab) November 4, 2020

https://twitter.com/thalassaemiaTIF/status/1325715357408120835

Why is Liverpool the flu jab manufacturing capital of the country? Is this why the mayor is so keen to stay on Johnson's good side? Is there a vaccine contract up for grabs? There are at least three vaccine companies in Speke alone! #KBF #CovidVaccine https://t.co/2VRdszJEF9

— SarcasticSooooooz #JFT96 #KBF #Abetterway (@goldjerrygold1) November 4, 2020

Seqirus Presents New Real-World Evidence on Relative Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older at IDWeek 2020 https://t.co/dPjCGTf2BZ

— IMPharma News (@IMPharmaNews) November 2, 2020

ツイッター検索で上記製薬会社名及び Japan や日本の5製薬会社各社名を入れて出て来たもの

The CoVIg-19 Plasma Alliance (Takeda, @bplplasmallc, @BiotestPlasma, @CSLBehring, @LFB_Group, @OctapharmaGroup, @AdmaBiologics, @BiomedPharmaGC, @sanquin, etc) has begun clinical production of a potential #COVID19 medicine. Help by donating plasma: https://t.co/q6Fe7VvHlG pic.twitter.com/Zcp4aNWpfh

— Takeda (@TakedaPharma) May 18, 2020

Takeda has joined forces with @bplplasmallc, @BiotestPlasma, @CSLBehring, @LFB_Group and @OctapharmaGroup to accelerate a potential treatment option for those at risk of serious complications from #COVID19. https://t.co/8MfTnO7olj pic.twitter.com/wimzKrVyh4

— Takeda (@TakedaPharma) April 23, 2020

Industry alliance brings together Takeda and other world-leading plasma companies, @BPLPlasmaLLC, @BiotestPlasma, @CSLBehring @LFB_Group and Octapharma, to accelerate development of a hyperimmune immunoglobulin medicine in the fight against #COVID19. https://t.co/ok9gZ1r1nf pic.twitter.com/mrpgUDg46l

— Takeda (@TakedaPharma) April 6, 2020

Ashfield proudly provides contact center support for #TheFightisInUs – joining global leaders, @Microsoft, @Takeda, @CSLBehring, @MayoClinic , @AdCouncil, @AmericasBlood in the campaign to collect life-saving #plasma from #COVID19 survivors. Learn more: https://t.co/J4vZzeYrpl pic.twitter.com/NKxwMWLxHl

— Ashfield Healthcare (@AshfieldCM) May 29, 2020

Australian biotech giant @CSL has formed a consortium with Takeda Pharmaceutical Company to develop a potential plasma therapy to fight #coronavirus. Story: https://t.co/TARpXMR76H pic.twitter.com/xNXtkLLd7v

— ManufacturersMonthly (@manmonthly) April 8, 2020

Toby Simon discussing the alliance between major producers of hyper-immune plasma therapies including @CSL_plasma @takeda and othershttps://t.co/fFH7rHJgUT #NewyorkBIO_COVID19

— NewYorkBIO (@newyorkbio) June 25, 2020

@CSLBehring is part of the CoVIg-19 Plasma Alliance that includes Biotest, BPL, LFB, Octapharma, Takeda, ADMA Biologics, BioPharma Plasma, GC Pharma, and Sanquin. @GatesFoundation is providing advisory support. Microsoft is providing technology. https://t.co/ctv0gLJiKI

— NCBIO (@ncbio) May 18, 2020

Biotest, BPL Group, LFB, and Octapharma have joined an alliance formed by CSL Behring and Takeda to develop a potential plasma-derived therapy for treating #COVID-19. https://t.co/yvjUnzLuVP @CSLBehring @TakedaPharma pic.twitter.com/YjtGyPdkQv

— Georgia Bio (@Georgia_Bio) April 6, 2020

CSL teams up with Takeda to create virus plasma treatmenthttps://t.co/S7Z6GXTj3T

— Financial Review (@FinancialReview) April 6, 2020

Key trial test begins for plasma-based COVID-19 therapy from Takeda, CSL https://t.co/dzdsNLhA5N

— cafepharma (@cafepharma) October 11, 2020

CSL and Takeda have isolated it and refined it into an anti-sera. CSL is the source for the plasma.
Trials begin this summer.https://t.co/nilSD0fo8G

— Timothy Gumm (@timothy_gumm) May 13, 2020

Japan approves #remdesivir to treat #COVID19; plus Takeda and CSL's Plasma Alliance will run its globulin trial with NIH, and a trio of Chinese biotechs partnered for an antibody therapy https://t.co/hKOoMUl3QM

— BioCentury (@BioCentury) May 8, 2020

As part of the global response against #COVID19 the #Swiss pharmaceutical company @OctapharmaGroup has joined with Biotest (Germany), BPL (UK), CSL Behring (Australia), Groupe LFB (France) and Takeda Pharma (Japan) to develop treatments. #SwissTechL39 https://t.co/UI3zppqkUt

— Swiss Embassy UK (@SwissEmbassyUK) April 16, 2020

‘It’s a humanitarian effort’: Led by Takeda and CSL Behring, a plasma coalition forms to fight #COVID-19. A new, worldwide coalition of plasma companies is seeking to develop and deliver a hyperimmune immunoglobulin therapy for… https://t.co/3HUIA8rTuX pic.twitter.com/LY0FsR10x4

— PIER MARIA FORNASARI (@PierFornasari) April 13, 2020

CSL Behring and Takeda Pharmaceutical Are Leading a Coalition to Develop a COVID-19 Hyperimmune Therapy @themotleyfool #stocks $TAK $CSLLY $EBS https://t.co/Lg69jmchXb

— Paula Schuck (@inkscrblr) April 10, 2020

CSL Behring and Takeda Pharmaceutical Are Leading a Coalition to Develop a COVID-19 Hyperimmune Therapy | NASDAQ https://t.co/uU7dcI4Nkl

— Economic Alliance of Kankakee County (@KankakeeCoEDC) April 9, 2020

quite a news here: big plasma-derived therapies' players (Biotest, Bio Products Laboratory, CSL, LFB, Octapharma and Takeda) join forces to immediately begin developing a non-company specific trademarked polyclonal hyperimmunoglobulin drug against SARS-CoV-2. https://t.co/agJaq44XX1

— Bertrand Delsuc (@BertrandBio) April 6, 2020

Says an organization w/ following roster of sponsors: 2019 Strategic Partners
Gold:
AstraZeneca
GSK
Merck & Co., Inc.
Pfizer Inc.
Sanofi Pasteur
Silver:
Janssen Therapeutics
Medicago Inc.
Bronze:
Seqirus, Inc. USA
Takeda https://t.co/DGLx3Lxfqh

— Plum Remson (@PlumRemson) November 10, 2019

Thank you again for our Virtual National Conference Sponsors for their continued support and dedication to the Alpha-1 Community. pic.twitter.com/A6ImAupRSS

— Alpha-1 Foundation (@AlphaFriend) June 29, 2020

Varicella Live Vaccine Market (impact of COVID-19) Demand, Growth and Opportunity 2020| Astellas Pharma Inc., CSL… https://t.co/02vQ6n1fqA >>> https://t.co/HTA6IsoHwv #strategy #competitiveintelligence #marketing #productmarketing #pharmaceutical #pharma #healthcare #biotech

— Dr Timos Papagatsias (@_timos_) July 18, 2020

The Global Vaccines Market Growth & Major Players – Astellas , CSL, Johnson & Johnson https://t.co/CV4KYxOA1i #VaccinesMarket #GlobalVaccinesMarket #VaccinesMarketSize #VaccinesMarketShare #VaccinesMarketTrends #VaccinesMarketGrowth #VaccinesMarketFuture #Vaccines

— Kriti Singh (@KritiSi62917720) May 30, 2019

Key players in the market include Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions, Inc. (US), GlaxoSmithKline plc (UK), Johnson & Johnson (US), MedImmune, LLC… https://t.co/ZZYfSHHK27

— PressRelease.cc (@PressRelease_cc) October 28, 2019

CSL is proud 2 announce that Dr. Bill Carson, CEO of Otsuka Pharma. Development & Commercialization joined our advisory team @elginthompson

— Culture Shift Labs (@CultureShiftLab) March 27, 2014

United States Influenza Vaccines Market 2018-2025 Analysis by emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi TanabePharma and Biondvax Pharmaceuticals Ltd, Seqirus, Sanofi Pasteur, GlaxoSmithKline (GSK) and AstraZeneca https://t.co/qQqrKL10Fm via @openPR

— DPI Research_Vaccine (@MarketR_Vaccine) November 5, 2018

Participants at the Asia Pacific and Japan Society of Hemostasis and Thrombosis conference shared perspectives on advances in #Haemophilia management, discussing options for individualised treatment #patientpromise pic.twitter.com/vJSgDfKyFh

— CSL (@CSL) July 9, 2018

To mark #WorldHaemophiliaDay, our colleagues in Japan share their heartfelt messages of support for the bleeding disorders community and demonstrate how we are driven everyday by our promise to patients. pic.twitter.com/CPGbZ7ULYj

— CSL (@CSL) April 17, 2018

Take a video tour of our new #CSLBehring office in Tokyo, #Japan. https://t.co/4mKVDWT1i6 pic.twitter.com/gPArofSVwx

— CSL Behring (@CSLBehring) July 15, 2019

We’re proud to bring 2 new options to #CIDP patients in Japan. https://t.co/HYxworDI6U pic.twitter.com/NCclP5p9ce

— CSL Behring (@CSLBehring) April 4, 2019

Our team in #Japan recently painted traditional Shisa sculptures as they reflected on past accomplishments and looked ahead to the future. pic.twitter.com/zOKXX5qCkG

— CSL Behring (@CSLBehring) August 9, 2017

Thank you to all – especially those in our Tokyo office – who helped bring our first #hemophilia product to Japan. https://t.co/MICGBFKdPg pic.twitter.com/gYYJpKe4fz

— CSL Behring (@CSLBehring) September 30, 2016

We're proud to bring our first #hemophilia product to Japan. https://t.co/sWn3BoCY3G pic.twitter.com/L6WvlTra6i

— CSL Behring (@CSLBehring) September 30, 2016

Our colleagues around the world took the #RedTieChallenge to support patients who have bleeding disorders. Japan! pic.twitter.com/Zdzm1PwMII

— CSL Behring (@CSLBehring) April 22, 2016

Despite the low awareness of patient groups in #Japan, healthcare professionals recognise the potential of patient representation in the #rarediseases space > https://t.co/bZIBH7dX3m via @CSLBehring pic.twitter.com/JcG4QtBbxy

— The Economist Intelligence Unit (@TheEIU) August 12, 2020

“Global biotherapeutics leader CSL Behring recently announced that Japan's Ministry of Health, Labour and Welfare has approved two of its immunoglobulin therapies for the treatment of patients with CIDP” https://t.co/jXmvuFEow5 pic.twitter.com/0J9uW53K2u

— CIDP Neuropathy (@CIDPNeuropathy) April 2, 2019

Japan Approves Berinert from @CSLBehring for Short-Term Prophylactic Treatment of HAE: https://t.co/6mZE48U2hd

— HAE International (HAEi) (@HAEDAY) March 24, 2017

CSL Behring's long-acting hemophilia B treatment Idelvion approved in Japan https://t.co/RsklhGEDr2 $QURE $ONCE $NVO $BAX

— Breaking News (@MarketCurrents) September 29, 2016

Takeda, Moderna partner up to bring 50M coronavirus shots to Japan | @TakedaPharma @Moderna_tx @Novavax @CSLBehring #Covid19 #Biotech #Vaccine #Deerfield #Cambridge #Massachusetts #Rockville #Maryland https://t.co/rP1SGKCnO9

— Pharm2Market (@pharm2market) October 31, 2020

Germany ドイツ Vol.5（pharmaceutical corporations 製薬会社）

All the below link and tweets are in English.

取り急ぎ以下貼っておきます。

Germany Vol.23 (pharmaceutical corporations: BioNTech)

上記リンク内に無い本日までのツイート

We provided an update on the potential timelines for the #COVID19 #vaccine candidate BNT162b2. We will seek approval only if the data provides a clear picture in three key areas: safety, efficacy, manufacturing quality. Read more in @WSJ by @bopanc. https://t.co/62njuhX3lu

— BioNTech SE (@BioNTech_Group) October 16, 2020

We are excited to welcome the latest addition to the BioNTech family: our colleagues in Marburg. The tech transfer is currently being made and we plan to start the production of potential #COVID19 vaccines in 2021. Welcome to #TeamBioNTech! pic.twitter.com/o9N26LmRoD

— BioNTech SE (@BioNTech_Group) November 2, 2020

One of the German #biotech firms working on a #CoronaVaccine, @BioNTech_Group, says results from study on effectiveness to come within next few days. Together with partner @pfizer will apply for FDA approval in 2 weeks. More on German vaccine development:https://t.co/cc92465OxM pic.twitter.com/YqwjNQds6O

— Germany Trade & Invest (@GTAI_com) October 30, 2020

https://twitter.com/InvestFlanders/status/1323176383582011394

Personalized #NeoantigenTherapy Plus #AntiPD1 | A Phase Ib Trial in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer | Lakshmi Srinivasan @BioNTech_Group @CellCellPress https://t.co/9NtpX0r8Bt | #2020_ReCapOct pic.twitter.com/2St8j5L624

— McHeyzer-Williams (@mmw_lmw) November 1, 2020

Engage with the community transforming the biotech sector at #BioIntegrates. Our one-day event will include interviews with Steve Bates, CEO, @BIA_UK and Sean Marett, Chief Business and Commercial Officer, @BioNTech_Group. Discover the full agenda: https://t.co/qynIgPU7rB pic.twitter.com/yJH4LzKuT2

— Life Science Integrates (@LSIntegrates) October 30, 2020

“The @UniofOxford/@AstraZeneca vaccine is expected to be one of the first from big #pharma to secure regulatory approval, along with @pfizer and @BioNTech_Group’s candidate" #ScienceNews #covid19news https://t.co/LgDPb8Eib4

— Life Science Rec. (@ScienceJobs) October 29, 2020

Comprehensive summary about the mRNA vaccine made in Mainz by Ugur, Özlem and the whole team of @BioNTech_Group and @tronmainz https://t.co/oqBicNHKrK

— Sebastian Boegel (@sebboeg) October 27, 2020

How a Little-known German Biotech Firm Founded by the Children of Turkish Immigrants Became a Leader in Global #Coronavirus Vaccine Race. ⁦My report via ⁦@WSJ⁩: https://t.co/FcSyXVccnC

— Bojan Pancevski (@bopanc) October 22, 2020

https://twitter.com/en_germany/status/1317834581048020993

@pfizer will apply for EUA from @US_FDA soon after they achieve the safety milestone of their experimental vaccine (developed with @BioNTech_Group) in the third week of November: https://t.co/WUtZ1UGrg5 #XerayaCapital #IndustryUpdates #COVID19 #Vaccine #Coronavirus pic.twitter.com/MQhAtL10oD

— Xeraya Capital (@xerayacapital) November 3, 2020

I continue to be #PfizerProud of all our colleagues, who delivered another strong quarter during these challenging times. The global phase 3 study for our #COVID19 vaccine candidate w/ @BioNTech_Group is ongoing at 150 sites with more than 42,000 participants enrolled. pic.twitter.com/ZCIzGMEDcJ

— AlbertBourla (@AlbertBourla) October 27, 2020

We are proud to organize the virtual @mrnaconference, the premier meeting destination for industry and academic professionals to explore the rapidly advancing science and business of #mRNA medicines. @BioNTech_Group @CureVacRNA @moderna_tx #eventplanning #vaccine #COVID19 pic.twitter.com/oKuuC0GpYA

— INTERPLAN Congress, Meeting & Event Management AG (@interplan_de) October 28, 2020

Richard B. Gaynor, MD, chair of the Accelerating Cancer Cures Advisory Committee, Damon Runyon board member, and President and Chief of Research and Development @BioNTech_Group U.S welcomes us to the virtual #CancerCures20 Symposium! pic.twitter.com/lArIzBNXKC

— Damon Runyon Cancer Research Foundation (@DamonRunyon) October 28, 2020

“@JNJNews plans to start testing its experimental #COVID19 #vaccine in youths aged 12 to 18 as soon as possible… Rival drugmaker @Pfizer has already begun testing the COVID-19 vaccine it is developing with Germany's @BioNTech_Group in children as young as 12.” #compliance https://t.co/PD9QxUCPag

— Mark Warner (@MAAWLAW) October 30, 2020

.@BioNTech_Group uses same mRNA technology as @moderna_tx. It never worked on anything, certainly not on vaccines, yet here we are.
Briefly discussed here: https://t.co/ccMuKcZYgi

— Leonid Schneider (visit my site for Covid19 cures) (@schneiderleonid) October 27, 2020

ツイッター検索で上記製薬会社名及び Japan や日本の5製薬会社各社名を入れて出て来たもの

We announced an agreement with #Japan for 120m doses of our mRNA-based vaccine candidate. This is part of our commitment to address the global health crisis together with @Pfizer as we hope it may help in bringing the world together at the #TokyoOlympics. https://t.co/YUmpvqELru pic.twitter.com/VcubAIgTvd

— BioNTech SE (@BioNTech_Group) July 31, 2020

Pfizer, BioNTech start combined trials of COVID-19 vaccine candidate in Japan https://t.co/nR8eZ56zeB pic.twitter.com/yyabGBd1x2

— Reuters (@Reuters) October 20, 2020

Pfizer, BioNTech to supply 120 million doses of coronavirus vaccine to Japan https://t.co/CPE5UL5WWR pic.twitter.com/iphKs1StYM

— Reuters (@Reuters) July 31, 2020

Pfizer Inc and BioNTech SE announced on Tuesday the start in Japan of combined Phase I and Phase II clinical trials of their mRNA vaccine candidate against the coronavirus.https://t.co/jm6bN39Is7

— Hindustan Times (@htTweets) October 20, 2020

Pfizer, BioNTech start combined trials of #COVID19 vaccine candidate in Japanhttps://t.co/jm6bN2S73x pic.twitter.com/TiA3mzGXfn

— Hindustan Times (@htTweets) October 20, 2020

Japan to get 120 mn doses of #COVID19 vaccine from Pfizer, BioNTechhttps://t.co/dVvgeYAlhU pic.twitter.com/P8U5kvtWr7

— Hindustan Times (@htTweets) July 31, 2020

Russia says its secretive Covid-19 vaccine is “a Sputnik moment” – ready to be launched in less than 2 weeks.

As some countries develop their own, others are both making and buying vaccines, including Japan which is procuring 120M doses from Pfizer and BioNTech pic.twitter.com/pHRmIAQSGs

— TRT World (@trtworld) July 31, 2020

Today we announced an agreement with the Ministry of Health, Labor and Welfare in #Japan to supply 120M doses of our #COVID19 #vaccine candidate in collaboration with @BioNTech_Group, subject to regulatory approval: https://t.co/FBbQN3ciRF pic.twitter.com/U402NeO6WA

— Pfizer Inc. (@pfizer) July 31, 2020

We’re committed to helping governments have access to breakthroughs. Today we announced an agreement w/ Japan to supply, subject to regulatory approval, 120M doses of the mRNA-based COVID-19 vaccine candidate being co-developed by @Pfizer & @BioNTech_Group https://t.co/PmZEsrCRgZ

— AlbertBourla (@AlbertBourla) July 31, 2020

Pfizer and BioNTech agreed to provide Japan with 120 million doses of the Covid-19 vaccine they’re developing https://t.co/EGTGMDOuVl

— Bloomberg Technology (@technology) August 1, 2020

Pfizer, BioNTech to make 120M vaccine doses for Japan https://t.co/6JkbuzH5ug pic.twitter.com/ZYhPQd5dv9

— BNN Bloomberg (@BNNBloomberg) July 31, 2020

PFE Stock Down 0.5%, Pfizer and BioNTech to Supply Japan with 120M Doses of COVID-19 Vaccinehttps://t.co/UXUi8CUCgI pic.twitter.com/eYc2Wj14qd

— Coinspeaker (@coinspeaker) July 31, 2020

• Japan signs deal to secure 120 million dose of potential coronavirus vaccine, German pharmaceutical group BioNTech says https://t.co/XrAeG2tzpX

— ABS-CBN News (@ABSCBNNews) July 31, 2020

Pfizer $PFE, BioNTech $BNTX to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidate https://t.co/Cww2CVC5jT pic.twitter.com/s2u8FoJU78

— Streetinsider.com (@Street_Insider) July 31, 2020

Pfizer, BioNTech score deal to supply 120M Covid-19 vaccine doses to Japan, writes @biotechvisigoth @medcitynews https://t.co/PSX9S2pMiz @BioNTech_Group $PFE $BNTX #COVID19

— MedCity News (@medcitynews) August 3, 2020

New post: Pfizer and BioNTech Supply Japan with 120 Million Doses of COVID-19 Vaccine Candidate BNT162 https://t.co/DLWtW6YYRt

— BiopharmaMASH (@bio_mash) August 1, 2020

Pfizer and BioNTech to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidate https://t.co/VajfZkzqfz @pfizer @BioNTech_Group More Transatlantic Life Science Business News at [LSUS] at https://t.co/HEEySVwfoy pic.twitter.com/PAdjZEeYAm

— [iito] Life Science (@iitoLifeScience) July 31, 2020

The #Covid19vaccine partnership of @BioNTech_Group and @pfizer inked its third supply pact in a week on Jul. 31. The #Japan government will take 120 million doses at an undisclosed price in the 2021 first half. It is the companies’ first #Asian agreement. https://t.co/jMHYIycNDk

— CHEManager International (@CHEManager_EU) August 4, 2020

US strikes $2.1bn #Covid19 vaccine deal with Sanofi $SAN and Glaxo $GSK, while Pfizer $PFE and BioNTech $BNTX to supply Japan with 120m vaccine candidate doses. More on the vaccine race in our podcast episode ➡️ https://t.co/LMsp4FXrx9 https://t.co/lOlbukINDP

— IGTV (@IGTV) July 31, 2020

Japan has signed a deal to secure 120 million doses of a potential coronavirus vaccine, German pharmaceutical group BioNTech, which is developing the drug with US pharma giant Pfizer, said Friday. | @AFP https://t.co/d9cryfWhNC

— Inquirer (@inquirerdotnet) July 31, 2020

Japan has signed a deal to secure 120 million doses of a potential coronavirus vaccine, German pharmaceutical group BioNTech, which is developing the drug with US pharma giant Pfizer, said. https://t.co/crihB500gj

— Philstar.com (@PhilstarNews) August 1, 2020

Japan has signed a deal to secure 120 million doses of a potential coronavirus vaccine, German pharmaceutical group BioNTech, which is developing the drug with US pharma giant Pfizer, said Fridayhttps://t.co/v8o7oVWaA0 pic.twitter.com/M0IDFS0Egu

— AFP news agency (@AFP) July 31, 2020

Pfizer, BioNTech to supply 120 million doses of COVID-19 vaccine to Japan https://t.co/bqSgv5pZnW

— Business Today (@BT_India) July 31, 2020

#Japan signs deal with #BioNTech to secure 120 million doses of potential #coronavirus vaccine#TheNews

— The News (@thenews_intl) August 1, 2020

Pfizer, BioNTech to supply 120m doses of virus vaccine to Japan.https://t.co/G8kN9ZwzaV

— Nikkei Asia (@NikkeiAsia) July 31, 2020

Pfizer, BioNTech to supply 120 mil doses of experimental coronavirus vaccine to Japan: Pfizer Inc and BioNTech SE have agreed to supply Japan with 120 million doses of their experimental coronavirus vaccine in the first half of 2021, the companies said… https://t.co/A5YL4MaTnk

— Japan Today News (@JapanToday) July 31, 2020

COVID-19 Vaccine Pipeline https://t.co/z9QJ2v4RBj via @kyodo_english #WHO @moderna_tx #NIAID @InovioPharma @BioNTech_Group #ClinicalResearch "Even if overseas vaccines have success and received special regulatory approval, the supply in Japan will be limited"

— ClinicalBid (@ClinicalBid) June 1, 2020

Japan signed a deal to secure 120 million doses of a potential coronavirus vaccine, German pharmaceutical group BioNTech said Friday, July 31.

FULL STORY: https://t.co/eVEI6JXlcN pic.twitter.com/F8l7Ze6UUl

— Rappler (@rapplerdotcom) August 1, 2020

BioNTech says the first deliveries to Japan are planned for the first half of 2021. https://t.co/SjcHtrTMy2

— Rappler (@rapplerdotcom) August 1, 2020

Takeda estimates £162.50 million hit to operating loss as Novartis withdraws from European approval for Xiidra. #TakedaPharmaceutical #Novartis #EMA #BionTech #StockMarketNews #Coronavirus #Xiidra #OperatingLoss #Asia @EMA_News https://t.co/qgyUjrECut pic.twitter.com/8m4LRpX2I3

— iNVEZZ (@InvezzPortal) June 29, 2020

Boston Globe story yesterday on how small businesses in Central Square, #CambMA have been impacted by covid-19. https://t.co/ItouzHJizj. Biopharma companies in Central Sq incl Novartis, Takeda, Blueprint, Spero, Voyager, Beam, AbbVie, Fulcrum, Rheos, Neon/BioNtech, Intellia

— Pearl Freier (@PearlF) September 6, 2020

Takeda teams up with Novavax to introduce its coronavirus vaccine in Japan | @Takedapharma @Novavax @Pfizer @BioNTech @AstraZeneca @UniofOxford #Vaccines #Covid19 #Biotech #MatrixM #Maryland #OperationWarpSpeed @JNJ https://t.co/82tpoKazFb

— Aspen Biosciences (@aspenbio) August 9, 2020

This week's EuroBiotech Report—Novo-Ablynx, Takeda-TiGenix, Scancell-BioNTech, Sanofi-Alnylam and Boehringer https://t.co/k5jkrKtv4M

— FierceBiotech (@FierceBiotech) January 11, 2018

U.K. イギリス Vol.31（pharmaceutical corporations 製薬会社）

All the below link and tweets are in English.

取り急ぎ以下貼っておきます。

UK Vol.170 (pharmaceutical corporations: GlaxoSmithKline)

上記リンク内に無い本日までのツイート

Today we, together with @Sanofi and @Gavi, announced a Statement of Intent to make available 200m doses of our Sanofi/GSK co-developed #COVID19 #vaccine to the COVAX Facility, if successful in clinical trials. Learn more: https://t.co/OYGgP1QpVk pic.twitter.com/pnKYUy15Dq

— GSK (@GSK) October 28, 2020

Our intent to supply the COVAX Facility (led by @gavi and @WHO) with 200m doses of our co-developed #COVID19 #vaccine, if successful in clinical trials, is key to ensuring equitable access for every country in the world and protecting those most at risk. https://t.co/CcPiEsruRN pic.twitter.com/ufnuOfxVJ3

— GSK (@GSK) October 28, 2020

Our recent announcement that we will make available 200m doses of the #vaccine we’re co-developing with @Sanofi to COVAX, could, if successful in clinical trials, be a key milestone to helping end this #COVID19 #pandemic. https://t.co/aje70UKtQz

— GSK (@GSK) October 29, 2020

Interesting insights from global experts on #pandemic prevention and preparedness, including the role of #vaccines, as we learn from #COVID19. (Subscription may be required). https://t.co/AgxJLWB3rA

— GSK (@GSK) October 30, 2020

We are proud to join @ScienceMagazine Top 20 Employers. Testament to bringing together great science, new tech, and outstanding people. @ScienceCareers #Innovation #SCTopEmployer pic.twitter.com/VzLEyNRS9I

— GSK (@GSK) October 31, 2020

Thanks to our own @EstOdek for highlighting what needs to happen so #BIPOC are represented, visible & celebrated in #Science. We’re inspired by her to continue building an inclusive environment where all scientists feel valued & can bring their best and authentic selves to work! https://t.co/5QdufNCgm7

— GSK (@GSK) October 30, 2020

Collaboration in the wake of #COVID requires trust. Our CSO Hal Barron talks about how our partnership with @Vir_Biotech came together in 18 days and why focus on critical issues is key in the @WSJ article: https://t.co/M8aC4lyR4a pic.twitter.com/2YkaIyu0pP

— GSK (@GSK) October 24, 2020

Our CSO Hal Barron and President of Global Vaccines Roger Conner spoke with @joewalkerWSJ about how #COVID19 is ushering in a new era of industry collaboration. https://t.co/hkKwkyLzEb

— GSK (@GSK) October 24, 2020

#DYK Most adults in the US aren't vaccinated against #HepA? #Hepatitis A can be transmitted through close contact w/ an infected person or through contaminated food or water. Talk to your doctor about vaccination.
Visit ➡️ https://t.co/cEV0x0F39t #LiverAwarenessMonth #NOhep pic.twitter.com/MVI3DVzUZO

— GSK US (@GSKUS) October 27, 2020

We’re supporting the voice of the patient by working together to eliminate access barriers at the Alliance for Health Policy, Voice of the Patient Health Summit 2020. #AHPSummit20 #patientvoice https://t.co/vki0yDOUVo

— GSK US (@GSKUS) October 26, 2020

Sanofi and @GSK have signed a Statement of Intent with the @gavi @WHO @CEPIvaccines #COVAX facility to secure the distribution of our #COVID19 vaccine worldwide: https://t.co/NB1oald3wH #SanofiActs pic.twitter.com/BXD2sLoh0h

— Sanofi (@sanofi) October 28, 2020

This year has shown unprecedented collaboration across our industry. Congratulations, John Shiver, SVP of R&D, @sanofipasteur, in partnership with @GSK, on being named one of @FiercePharma’s most influential people in the fight against #COVID19. https://t.co/I458tte4iO

— Sanofi US (@SanofiUS) October 27, 2020

Today we are proud to announce our intent to supply 200 million doses of our adjuvanted recombinant protein #COVID19 vaccine, if approved to #COVAX alongside @GSK. This will help offer timely and cost-effective access to vaccines worldwide.@gavi Learn more https://t.co/uRDSulc3zb pic.twitter.com/JrWpcOrGqu

— Sanofi Pasteur (@sanofipasteur) October 28, 2020

We are extremely proud of John Shiver, Senior Vice President of Vaccines Global R&D, for being named by @FiercePharma as one of the most influential people in the fight against #COVID19, in partnership with @GSK. https://t.co/LAIf0GT1Pr

— Sanofi Pasteur (@sanofipasteur) October 27, 2020

We’re pleased to announce we have signed a Statement of Intent to procure 200 million doses of the @Sanofi and @GSK #COVID19 vaccine candidate for the #COVAX Facility! https://t.co/4Pv6BtXFtn @CEPIvaccines @WHO

— Gavi, the Vaccine Alliance (@gavi) October 28, 2020

Very pleased that @Gavi has signed a Statement of Intent with @Sanofi and @GSK to provide 200 million doses of their adjuvanted recombinant protein #COVID19 vaccine to the #COVAX Facility! https://t.co/pUO6ntVnLR

— Seth Berkley (@GaviSeth) October 28, 2020

Thank you @sanofi for your partnership and commitment alongside @GSK to ensure that safe and effective #COVID19 vaccines reach those in greatest need around the world. Pleased to welcome your commitment to the #COVAX goal of equitable vaccine access. #OneWorldProtected https://t.co/QraLhRsyVZ

— Seth Berkley (@GaviSeth) October 28, 2020

Thank you @GSK for working with @Sanofi to help ensure the most at-risk groups, such as healthcare workers, have rapid access to doses of #COVID19 vaccines. I welcome your commitment to global health security! #OneWorldProtected https://t.co/DmS1X7Vwea

— Seth Berkley (@GaviSeth) October 28, 2020

https://twitter.com/scibus/status/1321454739364728834
https://twitter.com/MSF_access/status/1321890170808008706
https://twitter.com/MSF_access/status/1321935282971807744

MSF calling for transparency from pharmaceutical corporations around price, supply and distribution of the potential future #COVID19 vaccine @GSK @sanofipasteur https://t.co/bvbHBaHvsT

— Shailly Gupta (@Shaillytweeting) October 29, 2020

Pharmaceutical giant @GSK will attend this year’s China International Import Expo. So what's the latest from #GSK on developing a #COVID19 #vaccine? And What are the highlights of their new products and services this year? pic.twitter.com/LjTM34TvhI

— Frontline (@Frontlinestory) October 29, 2020

EU approves Zejula as monotherapy in ovarian cancer @GSK https://t.co/hwtquaFAOL pic.twitter.com/JZbY6VsktN

— The Pharma Letter (@ThePharmaLetter) October 30, 2020

Sanofi & GSK to supply 200m doses of their Covid-19 vaccine to global distribution scheme

Read it here: https://t.co/fiz2Tjk0vK @sanofi l @GSK l @gavi pic.twitter.com/cpmV0nOaXB

— EPM Magazine (@EPM_Magazine) October 29, 2020

https://twitter.com/UN_SPHS/status/1321745134149656576

COVID-19 Vaccine Update: Sanofi, GSK to Supply COVAX with 200 Million Doses of Coronavirus Vaccinehttps://t.co/mPLw6qMCC5 #COVID19Vaccine @sanofi @GSK #COVAX

— LatestLY (@latestly) October 29, 2020

The CEO of SBC Member Organisation @GSK is optimistic that a COVID-19 vaccine could be widely available in 2021. Find out more here:https://t.co/HmZgQgjY3w #COVID19 #covidvaccine pic.twitter.com/nREQEZsV93

— StevenageBioscience (@SteBioCat) October 28, 2020

Partner of #DMTR pic.twitter.com/LZPuOiyZlS

— riddler (@riddler_smitb) October 28, 2020

News for #pharma #marketers: Thurs, Oct 29

– @Sanofi, @GSK give 200 million COVID-19 vaccine doses to Covax
– @Pfizer will not report coronavirus vaccine results this month
– Podcast: @Genentech’s Quita Highsmithhttps://t.co/W779ysMOAh

— MM+M Magazine (@MMMnews) October 29, 2020

Dave Tudor and John Arthur of the Medicines Manufacturing Innovation Centre mark the start of construction of the MMIC today – exciting times for UK Life Sciences, manufacturing and Scotland! @Ivan_McKee @ukCPI @UniStrathclyde @GSK @AstraZeneca @scotent https://t.co/7LUCJl1Qpv pic.twitter.com/7zRN1fCmy5

— Life Sciences Scot (@LifeSciScot) October 26, 2020

White House “Vaccine Czar” Dr. Slaoui is using loopholes and working under a shady contract to skirt ethics laws that would require him to sell all his stock in COVID vaccine manufacturers. @RepKatiePorter and I want @GSA_OIG to investigate his contract.https://t.co/6EMTPBd9RN

— Elizabeth Warren (@SenWarren) October 30, 2020

https://twitter.com/TomDoddFCDO1/status/1321891577317511169

Construction has started on the Medicines Manufacturing Innovation Centre – a collaboration between Strathclyde, @ukCPI & industry partners @AstraZeneca & @GSK. The new centre will put Scotland at the cutting edge of advanced pharmaceutical manufacturing.https://t.co/4DJIQBQk3q pic.twitter.com/mdcz8iWBAm

— University of Strathclyde (@UniStrathclyde) October 28, 2020

Thanks to UCL for a charming virtual graduation ceremony ⁦@ucleastman⁩ ⁦@ucl_slms⁩ Thanks to ⁦@GSK⁩ and ⁦@basem_uk⁩ ⁦@PaedDentEastman⁩ ⁦@IanNeedleman⁩ for supporting Dr Julie Gallagher on her journey pic.twitter.com/kHemprO2oC

— Oral Health in Sport (@oralhealthsport) October 29, 2020

Get to know some of the #SCTopEmployers in #biotech #pharma and find job opportunities—Explore the 2020 Top Employer Profiles for @GSK, @Roche, and @pfizer:https://t.co/EsP0urWYqx pic.twitter.com/mR7pv1ZvEZ

— Science Careers (@ScienceCareers) October 30, 2020

Congrats @GSKUS @GSK ! pic.twitter.com/4kZMvS5V0Q

— Talend (@Talend) October 29, 2020

Congratulations to @CondeNast, in partnership with @tweetPHM on behalf of @GSK, for winning the Online Video or Film category for their work on “Well, Actually”!#DPIWeek2020 #FierceAwards #BeFierce pic.twitter.com/l0dZPLZJmx

— Digital Pharma (@DigitalPharma) October 28, 2020

Impressive presentation of Prof. Koen Kas, @kaskoen, at the @GSK meets Belgian University Event, talking about several #digital examples to turn sick care into #Healthcare! https://t.co/tWpJXVPQgc

— FlandersVaccine (@FlandersVaccine) October 27, 2020

Thank you @Amgen, @chemocentryxinc, @genentech, @GSK and @sanguinebio for sponsoring our Newly Diagnosed Patient conference happening this Saturday! Come see for yourself how their support is already giving vasculitis patients a better quality of life. pic.twitter.com/LsUrh5Y9Ar

— Vasculitis Foundation (@VasculitisFound) October 29, 2020

500 followers up! Shout out to our amazing @AI4VBH industry partners – thank you for all support so far!@ainostics @Biotronics3D @CydarMedical @GEHealthcare @innersightlabs @KheironMedical @MiradaMedical @NetAppUK @nvidia @PerspectumGroup @SiemensHealth @GSK pic.twitter.com/RfPYGgQzVe

— London AI Centre for Value Based Healthcare (@AI4VBH) October 28, 2020

ツイッター検索で上記製薬会社名及び Japan や日本の5製薬会社各社名を入れて出て来たもの

.@GSK and Daiichi Sankyo JV submits NDA for candidate #shingles vaccine in Japan https://t.co/rtg3TBFhCh pic.twitter.com/VJ1D4woI6R

— Pharma Tech Focus (@PharmaTechFocus) April 21, 2017

Anglo-Japanese JV announces Shingrix submission in Japan https://t.co/97zsKYDTBA #pharma @GSK @DaiichiSankyo @DaiichiSankyoJP

— The Pharma Letter (@ThePharmaLetter) April 19, 2017

Our president & CEO, Dr. Robert Preti says “since becoming part of Hitachi Chemical over a year ago, we have seen increasing interest in leveraging our PCT Global Service Platform both in the United States and Japan.” Learn about our partnership with @GSK: https://t.co/aS6Tfc9yKr

— Minaris Regenerative Medicine (@MinarisRM) October 30, 2018

#WIPOReSearch Member companies Eisai, GSK, Johnson & Johnson, and Takeda featured in November Partnership Hub Snapshot. Advancing drug discovery around #NTDs, #malaria, and #tuberculosis. https://t.co/rtLTaYv0uA @Eisai_SDGs, @GSK, @JNJGlobalHealth, @TakedaPharma, @WIPO pic.twitter.com/mnm0AJo3Ai

— BVGH (@BIOVentures) November 12, 2019

Great news that Takeda has joined the Open Targets drug discovery initiative. More here: https://t.co/XOHP4TPSpX @targetvalidate @TakedaPharma @GSK @emblebi @biogen https://t.co/8SFnDO41B2

— Sanger Institute (@sangerinstitute) December 5, 2017

Takeda joins Open Targets drug discovery initiative. @targetvalidate @TakedaPharma @GSK @emblebi @biogen https://t.co/XOHP4TPSpX pic.twitter.com/qPW97LuHPW

— Sanger Institute (@sangerinstitute) December 5, 2017

Open Targets is 5 and we would like to thank all our 355 staff from our partners @biogen @celgene @emblebi @GSK @takeda @sanofi @sangerinstitute + guest institutions for contributing & being part of such successful #precompetitive community. Here's to many more years to come! pic.twitter.com/eiVhWWVlXx

— Open Targets (@targetvalidate) June 21, 2019

GlaxoSmithKline, Teva, Takeda Investing in Global Sustainability Performance with the Responsible Health Initiative https://t.co/IfCIxQ9AQu via @ecovadis @GSK @Teva @tevapharmeurope @TakedaPharma @CDCGreenHealthy @bbchealth @Healthcare @HCPolicy @healthjourno1 @HCnewsEU

— EnvironmentalPartner (@MonikaWojcik) January 10, 2019

The Dementia Discovery Fund first launched in 2015 with $100 million in capital from a range of Big Pharma companies, the U.K. government and the non-profit Alzheimer's Research UK @Biogen @GSK @Johnson&Johnson @Lilly @Pfizer @Takeda @ARUK @DHSCgovuk https://t.co/tdtENajGGx

— The Dementia Discovery Fund (@TheDDFund) August 9, 2018

236 preclinical pharma-academia #partnerships in 2015. @GSK at the top, followed by Bristol-Myers Squibb and Takeda https://t.co/ThlU1DygfF

— Giuseppe Recchia (@GGRecchia) March 26, 2016

In new best practice, 8 #pharma companies found by #AMRB2020 to have clinical-stage medicines that qualify as truly new – meaning they are more likely to remain effective for longer against resistant pathogens.https://t.co/ElTPlzfSRr @GSK @nabriva @Otsuka @scynexis @Summitplc pic.twitter.com/WtaCMcJTuA

— Access to Medicine Foundation (@AtMIndex) February 15, 2020

Did you hear? #JNJ is joining forces with @GatesFoundation, @Evotec, @GSK and Otsuka to develop a universal #TB treatment regimen. Learn how this unique collaboration builds on the #JNJ commitment to transform #TB treatment and #endTB for good ➡️ https://t.co/lJP54H0eGv pic.twitter.com/3TTCK3UHdu

— Johnson & Johnson Global Health (@JNJGlobalHealth) March 5, 2020

#WIPOReSearch Member companies Eisai, GSK, Johnson & Johnson, and Takeda featured in November Partnership Hub Snapshot. Advancing drug discovery around #NTDs, #malaria, and #tuberculosis. https://t.co/rtLTaYv0uA @Eisai_SDGs, @GSK, @JNJGlobalHealth, @TakedaPharma, @WIPO pic.twitter.com/mnm0AJo3Ai

— BVGH (@BIOVentures) November 12, 2019

On #WorldMosquitoDay, we want to thank our pharmaceutical partners for donating over seven billion life-changing treatments for #elephantiasis since 2012. #beatntds #endtheneglect @Eisai_SDGs @GSK pic.twitter.com/sYOaNgSfDE

— UnitingtoCombatNTDs (@CombatNTDs) August 20, 2020

Together with the Haitian Ministry of Health (MSPP) and our partners @GSK and @Eisai_SDGs, we are closer to eliminating a painful & disfiguring disease. #BeatNTDs

Learn more about our work in Hispaniola here: https://t.co/qFvEVXsITc pic.twitter.com/orZuiKoDGV

— The Carter Center (@CarterCenter) March 23, 2020

New #paediatric treatments recently launched for #HIV #soiltransmittedhelminths #epilepsy and #pneumonia from 4 companies detailed in #atmi2018 today: @GSK @JNJNews @Merck @eisai …. #worldChildrensDay2018 #WorldChildrensDay https://t.co/qnb3DoC0m1

— Danny Edwards (@dannyjedwards) November 20, 2018

A huge thank you to our Corporate Volunteers that have been coming in to help us with maintenance and gardening around the site. Thank you to Eisai, @NatWest_Help Bishop's Stortford, '@GivingMachineUK , @GSK and @Tesco it is greatly appreciated! pic.twitter.com/fxNrSocTeO

— St Elizabeth's Centre (@St_Elizabeths) July 17, 2018

On #WorldNTDDay we celebrate our industry partnerships to #beatNTDs including the innovative Drug Discovery Booster to discover new drugs with @abbvie @AstellasUS @AstraZeneca @bmsnews @Eisai_SDGs @merckgroup Shionogi & @TakedaPharma. pic.twitter.com/j4Xgs60vO2

— Drugs for Neglected Diseases initiative (@DNDi) January 30, 2020

#NTD supply chain at #Merck attended by #Eisai, @pfizer @GSK #MSD @JNJNews @DeutschePostDHL on #schistosomiasis pic.twitter.com/ViNezXdIKC

— Merck (@merckgroup) June 28, 2016

#BreakingNews for #investors and #media: First approval of daprodustat (Duvroq) received in Japan.

— GSK (@GSK) June 29, 2020

https://twitter.com/GSK/status/1275710004411187206
https://twitter.com/GSK/status/880055699820093440

We’re partnering with @GatesFoundation, @wellcometrust & govts from Germany, Japan & Norway to #outsmartepidemics: https://t.co/vBcq9Mjy8q pic.twitter.com/wLo1DQidw6

— GSK (@GSK) January 19, 2017

.@GSK's drug for anaemia caused by chronic kidney disease daprodustat has been approved in Japan, taking on a recently approved rival from Astellas https://t.co/FMPlzKUJ69

— pharmaphorum (@pharmaphorum) June 29, 2020

Chasing #Astellas and #Mitsubishi, #GSK files for Japanese approval of oral #anemia drug https://t.co/X7cihSiIXO @FierceBiotech @GSK #daprodustat

— Plexus Ventures (@PlexusVentures) August 22, 2019

.@GSK lands 1st approval for #Duvroq as Japan greenlights drug for renal anemiahttps://t.co/ZK5FYlDf8Z $GSK pic.twitter.com/Fg8sAlJhGa

— Market Intelligence: Healthcare (@SPGMIHealthcare) June 29, 2020

GSK receives regulatory approval for Duvroq (daprodustat) in Japan in anaemia due to chronic kidney disease https://t.co/bsks1Wrmvg @GSK More Asian life science business news at [LSA] at https://t.co/BOlw85yA1L pic.twitter.com/s4Y83zBEcQ

— [iito] Life Science (@iitoLifeScience) June 29, 2020

GSK/ViiV: Dovato (dolutegravir/lamivudine), once-daily, single-pill, 2-drug regimen for HIV-1, granted marketing approval by Japan Ministry of Health, Labour and Welfare https://t.co/GF5h5nwtqV @GSK @ViiVHC More Asian life science business news at [LSA] at https://t.co/o0PHiM2bwA

— [iito] Life Science (@iitoLifeScience) January 15, 2020

Check out new #DRG epidemiology data and forecast on #herpeszoster incorporating the new #vaccine trends of #shingrix across the United States, Western Europe and Japan – live now! @DRGinsights @GSK #Shingles #VaccinesSaveLives https://t.co/r92nrjfqvg https://t.co/8zvj8CWrfZ

— DRG Epidemiology (@DRG_Epi) February 21, 2019

To take the shot or not? #DRG epidemiology report forecasts over 400 million people eligible for #influenzavaccine in 2019 across the United States, Western Europe and Japan. Check out the detailed report @DRGinsights @GSK #flu #vaccinateforlife #fluseason #Influenza https://t.co/TkI62MgvXF

— DRG Epidemiology (@DRG_Epi) January 30, 2019

Japan approval for Darzalex and Benlysta https://t.co/lCa7sYMMr4 @Genmab @JanssenGlobal @GSK #pharma

— The Pharma Letter (@ThePharmaLetter) September 27, 2017

.@GSK #SHINGRIX containing $AGEN QS-21 Stimulon® received approvals in US, Canada, and now in Europe & Japan for #prevention of #shingles in adults >=50 [https://t.co/qfmmLw3SRf]; Details here [https://t.co/Lw9n7kRgI1]. QS-21 is a part of Agenus’ neoantigen vaccine #AutoSynVax.

— Agenus Inc. ($AGEN) (@Agenus_Bio) March 26, 2018

#Pharma with '#AI friendly' executives will prosper: US, Germany, and Japan-based companies lead the pack, says @DK_Analytics report // @DeepTech_VC

Read: https://t.co/Ra1FDwHAXE @Boehringer @GSK @LillyPad @Evotec @pfizer @Amgen @BayerPharma @Roche @Novartis @bmsnews @Merck pic.twitter.com/df32pzpwpr

— Outsourcing-Pharma (@OutsourcPharma) July 8, 2019

J&J, Sanofi and more look to ink national COVID-19 vaccine supply pacts in EU, Japan: reports | @AstraZeneca @JNJ @gatesfoundation @melindagates @BillGates @UniofOxford @BARDA @Sanofi @Moderna @Pfizer @BioNTech @Curevac @GSK #covid19 #vaccine #Biotech https://t.co/cRcjPrjCy9

— Aspen Biosciences (@aspenbio) July 19, 2020

On Monday, J. Sampson (@RobertWaltersJP), J. Spraggs (@GSK) and H. McLeish (@Japan_EY) kicked off the BCCJ's '#COVID19 Default to Action' webinar series.

Watch the full webinar, 'The Leadership Challenge', here: https://t.co/oix01kECMu pic.twitter.com/BhKaOagSdE

— British Chamber of Commerce in Japan (@BCCJapan) March 19, 2020

The nominees for the Diversity & Inclusion #2018BBAs are . . .
– @custommediakk
–@Freshfields Bruckhaus Deringer
– @GSK Japan
– @HoganLovells
-Intralink
– @LloydsofLondon Japan

Learn more about the nominees: https://t.co/KiQHd9dQX8 pic.twitter.com/ggzYLD8Qzk

— British Chamber of Commerce in Japan (@BCCJapan) October 30, 2018

Science and Technology 科学技術 Vol.12（pharmaceutical products 医薬品 Vol.5：influenza vaccines インフルエンザワクチン）

All the below links and excerpts are in English.

取り急ぎ標記関連リンクと当方作成の抜粋を以下のとおり貼っておきます。

Key Facts About Seasonal Flu Vaccine | @CDCgov

Flu Vaccination
How do flu vaccines work?
Flu vaccines cause antibodies to develop in the body about two weeks after vaccination. These antibodies provide protection against infection with the viruses that are used to make the vaccine.
The seasonal flu vaccine protects against the influenza viruses that research indicates will be most common during the upcoming season. Most flu vaccines in the United States protect against four different flu viruses (“quadrivalent”); an influenza A (H1N1) virus, an influenza A (H3N2) virus, and two influenza B viruses. There are also some flu vaccines that protect against three different flu viruses (“trivalent”); an influenza A (H1N1) virus, an influenza A (H3N2) virus, and one influenza B virus. Two of the trivalent vaccines are designed specifically for people 65 and older to create a stronger immune response.
What kinds of flu vaccines are available?
CDC recommends use of any licensed, age-appropriate influenza vaccine during the 2020-2021 influenza season, including inactivated influenza vaccine [IIV], recombinant influenza vaccine [RIV], or live attenuated influenza vaccine (LAIV). No preference is expressed for any influenza vaccine over another. Both trivalent (three-ingredient) and quadrivalent (four-ingredient) influenza vaccines will be available.
Quadrivalent flu vaccines include:
Standard-dose quadrivalent influenza shots that are manufactured using virus grown in eggs. These include Afluria Quadrivalent, Fluarix Quadrivalent, FluLaval Quadrivalent, and Fluzone Quadrivalent. Different influenza shots are licensed for different age groups. These four vaccines are approved for people 6 months of age and older. Most influenza shots are given in an arm muscle with a needle. One quadrivalent influenza shot (Afluria Quadrivalent) can be given either with a needle (for people aged 6 months and older) or with a jet injector (for people aged 18 through 64 years only). …
Are any of the available flu vaccines recommended over others?
…the Advisory Committee on Immunization Practices (ACIP) recommends…including inactivated influenza vaccine (IIV), recombinant influenza vaccine (RIV), or live attenuated nasal spray influenza vaccine (LAIV4)…
Who Should Not Be Vaccinated?
… Factors that can determine a person’s suitability for vaccination, or vaccination with a particular vaccine, include a person’s age, health (current and past) and any allergies to flu vaccine or its components. …
Flu and COVID-19
Does a flu vaccine increase your risk of getting COVID-19?
Vaccine Effectiveness
Can I get seasonal flu even though I got a flu vaccine this year?
What protection does a flu vaccine provide if I do get sick with flu?
Vaccine Benefits
What are the benefits of flu vaccination?
Vaccine Match
What if circulating viruses and the vaccine viruses are different?
Why is there sometimes not a good match between a vaccine virus and circulating viruses?
Flu viruses are constantly changing (called “antigenic drift”) ? they can change from one season to the next or they can even change within the course of one flu season. Experts must pick which viruses to include in the vaccine many months in advance in order for vaccine to be produced and delivered on time. …
… While all influenza viruses undergo changes when they are grown in eggs, changes in influenza A(H3N2) viruses are more likely to result in antigenic changes compared with changes in other influenza viruses. These so-called “egg-adapted changes” are present in most of the vaccine viruses recommended for use in egg-based vaccine production and may reduce their potential effectiveness against circulating influenza viruses. …
Vaccine Side Effects (What to Expect)
Can a flu vaccine give me flu?
No, a flu vaccine cannot cause flu illness. …
What side effects can occur after getting a flu vaccine?

Flu Vaccine (Flu Shot) | @MedicineNet
Facts you should know about the influenza vaccine (flu shot)
・Types of influenza (flu) vaccines include the injection (killed virus), recombinant (made without flu virus), and nasal spray vaccines (containing live virus). …
What is influenza (flu)?
… Flu is a respiratory infection, that is, an infection that develops primarily in the lungs. People often call respiratory infections caused by other viruses the flu, but this is incorrect. These other infections are usually categorized as URIs (upper respiratory infections) and have multiple causes. …
Influenza viruses are divided scientifically into three types, designated A, B, and C. Influenza types A and B are responsible for epidemics of respiratory illness that occur almost every winter. Influenza type C usually causes either a very mild respiratory illness or no symptoms at all; it does not cause epidemics and does not have the severe public health impact of influenza types A and B. Type A viruses are divided into subtypes and are named based on differences in two viral surface proteins called hemagglutinin (H) and neuraminidase (N). There are 16 known H subtypes and nine known N subtypes. …
The so-called swine flu pandemic of 2009 was caused by a novel influenza A virus designated H1N1 based upon its surface protein types. This virus was originally referred to as swine flu because many of the genes in this new virus were very similar to influenza viruses that normally occur in pigs in North America. However, this virus was actually quite different from the typical swine flu viruses found in pigs.

Types of seasonal influenza vaccine | @WHO_Europe
Two types of influenza vaccine are widely available: inactivated influenza vaccines (IIV) and live attenuated influenza vaccines (LAIV). Traditionally, influenza vaccines (both IIV and LAIV) have been produced to protect against 3 different seasonal influenza viruses (also called trivalent vaccines). In most countries this is still the case and the current trivalent vaccines contain influenza A(H3N2), pandemic A(H1N1) and 1 of 2 influenza B lineage viruses. However, recently vaccines which protect against 4 different viruses, including both influenza B lineage viruses (quadrivalent vaccines), have become available in some countries. …
Annual selection of viruses
The composition of influenza vaccines (both IIV and LAIV) are updated annually by WHO based on information gathered from the Global Influenza Surveillance and Response System (GISRS)…

Flu vaccine | @NHSuk
Flu vaccine and coronavirus (COVID-19)
Flu vaccination is important because:
・if you’re at higher risk from coronavirus, you’re also more at risk of problems from flu
・if you get flu and coronavirus at the same time, research shows you’re more likely to be seriously ill
・it’ll help to reduce pressure on the NHS and social care staff who may be dealing with coronavirus
If you’ve had COVID-19, it’s safe to have the flu vaccine. It’ll be effective at helping to prevent flu.

Influenza Vaccine for the 2020-2021 Season | @US_FDA
Influenza Vaccine (Flu Shot and Nasal Spray) for Adults | @WebMD
Q&A on Influenza (English; 11/21/2019) | 厚生労働省

World 世界情勢等 Vol.7

All the below links are in English.

取り急ぎ以下貼っておきます。

World Vol.51
World Vol.50
World Vol.49
World Vol.48
World Vol.47
World Vol.46
World Vol.45
World Vol.44
World Vol.43
World Vol.42
World Vol.41

U.S.A. アメリカ Vol.123（New Jersey ニュージャージー州 Vol.4: pharmaceutical corporations 製薬会社）

All the below link and tweets are in English.

Vol.122 (New Jersey ニュージャージー州 Vol.3: pharmaceutical corporations 製薬会社）の続き

ツイッター検索で上記製薬会社名及び Japan や日本の5製薬会社各社名を入れて出て来たもの

Japan's PeptiDream to work with Merck in developing COVID-19 therapies https://t.co/GzIqX0LbZQ pic.twitter.com/T8MxO4ZuZu

— Reuters (@Reuters) June 12, 2020

CDC Director Brenda Fitzgerald bought stock in Japan Tobacco, Merck and Humana– *AFTER* she became the nation's top public health official.

The investigation from @SarahKarlin
& @Briannaehley: https://t.co/gHNHqOP8IG

— Adam Cancryn (@adamcancryn) January 30, 2018

During COVID, the growing dangers and threat posed by antibiotic-resistant bacteria outweigh the global level of preparedness. Meanwhile, antibiotic R&D is suffering for investment. Forge applauds @Merck and Kyorin for supporting @PewCharitableTrust https://t.co/i0ToNjccgt

— Forge Therapeutics (@ForgeThera) October 23, 2020

New data from Merck, Kyorin shared to Pew's SPARK @pewtrusts @Merck https://t.co/ibg9R6JXFn

— The Science Advisory Board (@ScienceBoard) October 21, 2020

“Our hope is that the data from @Merck’s research will help catalyze discovery of new #antibiotics for Gram-negative pathogens,” @pewhealth’s @KathrynTalking says of the pharmaceutical company’s recent data contribution to SPARK. https://t.co/qd6oOf3y15

— Save Antibiotics (@saveantibiotics) October 21, 2020

Japan Prize / Merck-Banyu Lectureship for Naoya Kumagai / DECHEMA Prize for Timothy Noeel (News) https://t.co/npKfaLlQBg pic.twitter.com/6Q1xQyXK11

— Angewandte Chemie (@angew_chem) April 26, 2018

@MSD_JAPAN

In today's News Briefing: Two years unveiling a flop in their first PhIII trial of guadecitabine as a frontline treatment, Otsuka is back with 2 more pivotal setbacks. And the #FDA approved an expanded indication for Merck’s best-seller Keytruda. https://t.co/5svHdzG7UG

— Endpoints News (@endpts) October 16, 2020

Merck adds to lung cancer wall with Otsuka deal https://t.co/l9RW0Njibg pic.twitter.com/GnYs2TWMeI

— HealthIT and Biotech (@UCCharting) January 9, 2020

Merck adds to lung cancer wall with Otsuka deal | BioPharma Dive https://t.co/k063lZ3W8E

— Mr. Brian Uberig (@Brian_Uberig) January 8, 2020

MSD enlists Otsuka units Taiho and Astex to develop KRAS therapies https://t.co/2QOB4obxMj #pharma #healthcare

— PharmaTimes (@PharmaTimes) January 8, 2020

Merck and Otsuka enter into a research and development pact for a drug that targets a dangerous subset of cancers https://t.co/8ESVh069oT

— Bloomberg (@business) January 7, 2020

Merck & Co. partners with Otsuka units Taiho, Astex on cancer drug development https://t.co/qu7yCDMN5P $MRK $ASTX

— FirstWord Pharma (@fwpharma) January 6, 2020

Industry Insight of Oncolytic Virus Market Research Segment, In-depth Analysis | Merck, Otsuka Pharmaceutical Co, Pfizerhttps://t.co/lnfmzWgTWA #news #pharma #pharmiweb

— Pharma News (@pharminews) December 24, 2019

Oncolytic Virus Market Analysis and Reviews 2019 to 2025 | Merck, Otsuka Pharmaceutical Co, Pfizer, Roche, Cold Genesys, Genelux https://t.co/5MnJLhS6t2 pic.twitter.com/4THnWUqxql

— Science Examiner (@ScienceExaminer) October 7, 2019

Analyst Keshalini Sabaratnam @Pharma_GD on the #sales #forecast for @Merck and #Otsuka 's #Keytruda (pembrolizumab) projected to be top drug by 2023 and what does this mean for their #contractmanufacturers #CDMO #CMO @AstraZeneca @BoehringerDE https://t.co/R6Wmwcm2Qb

— GlobalData PharmSource (@PharmSource) October 2, 2019

The $200 discount for the Marketing Disruption Summit ends Friday! Explore the full agenda and get your tickets here: https://t.co/sueo5mBZEd #sanofi #BMS #ferring #boehringeringelheim #merck #teva #gsk #abbvie #astrazeneca #pfizer #bayer #otsuka #us #pharma #marketing #data #it pic.twitter.com/u9P8j4mLcn

— Reuters Events Pharma (@RE_Pharma) August 14, 2019

Otsuka buying Waltham, Mass.-based antibody specialist Visterra for $430 million, all-cash. https://t.co/FIwi2S4VeB

Last valuation was $188 million, per Pitchbook. Omega, Alexandria, Cycad Group, Gates Foundation, Merck, Vertex, Temasek, Alexandria among investors.

— Matthew Herper (@matthewherper) July 11, 2018

"Editor’s note: The author did not initially disclose having received payments from Boehringer Ingelheim, Eli Lilly, Hoffmann-La Roche, Lundbeck, Merck, Sharpe, and Dohme, Otsuka, Pfizer, and other companies." You have to ask – why the delay? @AmerGeriatrics https://t.co/RWpZYRJ7zK

— James Richardson, MD, MPH (@DocRock54) March 10, 2018

Merck and Otsuka US agree: Misalignment in healthcare is our biggest cha… https://t.co/H2U3iCqVZ1 via @YouTube

— Tim Nolan (@TimNolan1941) August 17, 2017

ESMO: Where will Merck, Eisai take Keytruda-Lenvima next? Ovarian and colorectal cancer could be good options, data show https://t.co/mjqD8dcsru

— cafepharma (@cafepharma) September 20, 2020

Chasing Merck, Eisai launches insomnia drug Dayvigo in Japan https://t.co/e3JM6pAqPX

— cafepharma (@cafepharma) July 7, 2020

https://twitter.com/LRamseu/status/1312391912956010498

Merck, Eisai's Keytruda-Lenvima combo stonewalled in liver cancer after Roche's first-in-class green light #livercancernews https://t.co/uJyJ0rpuoG

— Blue Faery (@BlueFaeryLiver) September 16, 2020

US rejects MSD/Eisai's Keytruda Lenvima combo https://t.co/U6bwJRTYcK #lifesciences #news

— PharmaTimes (@PharmaTimes) July 9, 2020

Merck, Eisai's Keytruda-Lenvima combo stonewalled in liver cancer after Roche's first-in-class green light https://t.co/fCgfHt2mPc

— FiercePharma (@FiercePharma) July 8, 2020

Merck, Eisai to put experimental cancer combination in new clinical trial https://t.co/LuQoPj699g

— MarketWatch (@MarketWatch) July 8, 2020

Merck, Eisai to put experimental cancer combination in new clinical trial https://t.co/uoyKGe8up0

— MMC Anchor (@MMCAnchor) July 8, 2020

ASCO: Merck, Eisai pad case for liver cancer nod with Keytruda-Lenvima combo data https://t.co/f6piWgmPOf

— EIPG (@EIPGeu) June 1, 2020

.@Merck/@Eisai's Keytruda/Lenvima combo 1st to win simultaneous approvals from @US_FDA, @GovCanHealth & @TGAgovau under new international regulatory program for #cancer drugs, writes @biotechvisigoth. $MRK #oncology https://t.co/nAfqQ8mUqL

— MedCity News (@medcitynews) September 18, 2019

New #paediatric treatments recently launched for #HIV #soiltransmittedhelminths #epilepsy and #pneumonia from 4 companies detailed in #atmi2018 today: @GSK @JNJNews @Merck @eisai …. #worldChildrensDay2018 #WorldChildrensDay https://t.co/qnb3DoC0m1

— Danny Edwards (@dannyjedwards) November 20, 2018

#Eisai, #MSD start marketing activity for #LENVIMA https://t.co/qGiJ2CwZx0 via @AsiaBioSpectrum

— Sudam Walekar (@sudam_walekar) October 23, 2018

Eisai and MSD Japan Commence Collaboration on Commercialization Activities for LENVIMA (Lenvatinib) in Japan https://t.co/oLX4MT3Vnu

— EIN Presswire: Merck Newswire (@EINMerckNews) October 22, 2018

Eisai/MSD’s Lenvima approved in Europe for liver cancer https://t.co/pPxoYTKCzG pic.twitter.com/Itatzdg438

— PIR International (@PIR_Intl) August 28, 2018

Merck, Eisai win FDA approval for Lenvima to treat unresectable HCC https://t.co/5tlVxTAiLO

— NGT Consulting (@NextGeneTherapy) August 20, 2018

Eisai and MSD team up to combine Lenvima and Keytruda in cancer https://t.co/K7XtG4RWnv pic.twitter.com/R9fukbkYeX

— Pharmamarketeer (@Pharmamarketeer) March 13, 2018

Merck partners with Eisai's Tyrosine Kinase inhibitor drug Lenvatinib with apotential deal of over 5 billion dollars#merck #Eisai #Checkpointinhibitor #Tyrosinerkinaseinhibitor #combination #billiondollar #deal #treat #malignancies https://t.co/NXsLRtc17N

— Neil Sankar (@SankarNeil) March 12, 2018

Merck and Eisai Ink $5.76B Cancer Deal https://t.co/bKH5FnuCC9 pic.twitter.com/RI1iJIIqLI

— Biotech World (@BiotechWorld) March 9, 2018

Eisai and MSD will jointly develop and commercialize a thyroid cancer therapy – https://t.co/Z1TfQSlksY pic.twitter.com/QVLB0ppzJT

— GMPnews.Net (@GMPnewsNet) March 8, 2018

Our final panel session at @PharEast2018 features Representatives from @JNJCares, Eisai Japan, MSD Singapore and Fosub-kite discussing on using real world evidence (RWD) to support the rational use of medicine in Asia. #phareast pic.twitter.com/LD4Y0kmqE4

— Phar-East (@PharEast2018) March 2, 2018

@gatesfoundation , @wellcometrust & @Mastercard Launch Initiative to Speed Development and Access to Therapies for COVID-19#COVID19TherapeuticsAccelerator #Covid19 https://t.co/ATA8tRBLc7 #BD #BI #Eisai #EliLilly #Gilead #GSK #JandJ #MSD #Merck #Novartis #Pfizer #Sanofi

— Claude Waddington (@Mr_C_Wadd) March 30, 2020

MSD and Eisai announce meaningful objective response rates for Keytruda+Lenvima combo in two cancer patient populations https://t.co/dRtWAbK5fk #pharma pic.twitter.com/2YDFuIMvrs

— Pharmafocus (@Pharmafocus) May 29, 2020

Eisai and MSD's Lenvima recommended for NHS Scotland in advanced or unresectable #LiverCancer https://t.co/bhdX1Yb5qR #cancer #pharma #NHS pic.twitter.com/H2qvj5SrrE

— Pharmafocus (@Pharmafocus) April 8, 2019

Thank you to our No One Fights Alone Virtual Gala Celebration sponsors, including Platinum Ribbon Sponsors, Amgen, Merck, Oncosec Immunotherapies, and Silver Ribbon Sponsors, Eisai and Immunomedics. Your generosity and support make it all possible. https://t.co/B8RsqHB5bW pic.twitter.com/KungeoGTTb

— TNBC Foundation (@TNBCFoundation) October 23, 2020

These pharma fleecers, including Takeda, Eisai, Merck, and Genentech, choose to sell their expensive oncology drugs in excessively large drug vials that lead to waste. They got my second #PharmaFleeceAward today.

— Senator Dick Durbin (@SenatorDurbin) March 14, 2019

Daiichi Sankyo signs clinical trial collaboration deal with Merck and Pfizer: Daiichi Sankyo has entered into a clinical trial collaboration agreement with Merck and Pfizer to evaluate the combination of its [fam-] trastuzumab deruxtecan (DS-8201) with… https://t.co/N83w7zGYxv

— cafepharma (@cafepharma) October 26, 2018

Daiichi-Merck partnership lines up Keytruda combo therapy https://t.co/YnoL7Sa9B6 pic.twitter.com/9Ocwq2ei5F

— JackLeckerman (@JackLeckerman) October 9, 2018

Daiichi Sankyo has entered into a clinical trial collaboration agreement with a subsidiary of MSD to evaluate a potential new combination therapy for breast or lung cancershttps://t.co/i08ieVPnZY pic.twitter.com/F3ZuKh8KUs

— Bio_Talent (@bio_talent) September 28, 2018

Unfortunately message is suspect bc of COI. F. Schiele reports personal fees from Board membership, consultancy, or lecturing from Sanofi, Amgen, Pfizer, AZ, MSD, BMS, Bayer & Daiichi-Sankyo. Steen Dalby Kristensen has recd lecture fees from AZ, Bayer, BMS/Pfizer and Boehringer- https://t.co/mKikYa72D9

— Ram Charan (@RamCharanji) January 11, 2018

Global Fibromyalgia Drugs market 2020: focuses on companies, opportunities, market size, growth, revenue & forecast 2026 | COVID19 Impact Analysis | Key Players: Pfizer, Eli Lilly, Actavis, Merck Sharp and Dohme, Daiichi Sankyo, etc. | InForGrowth – The … https://t.co/Z61iSQQlKs

— FMS News bot (@fmsbot) October 2, 2020

Hyperlipidemia Market: Market Data, Industry Analysis, Size,Share 2027 | Leading Players- AstraZeneca, Sanofi, Merck & Co., Pfizer, Daiichi Sankyo Company https://t.co/Wbz8agTS65

— Harshad Ramesh Borde (@BordeHarshad) August 25, 2020

The Next Boom Sector: Cancer

Physiomics #PYC is a leading oncology consultancy using its proprietary state of the art Virtual Tumour technology to predict and better understand effects of cancer treatments

Clients:
Merck, Astellas, Bicycle, Valirx, Cyclacel, CellCentric etc pic.twitter.com/djRsMNxJsc

— Stockonomist (@Stockonomist) September 28, 2020

Thanks to our @ANZUPtrials #bestofGUoncology #ANZUPGU19 sponsors – @IpsenGroup Astellas Oncology @AstraZeneca @MSD_Aus pic.twitter.com/WtTfQE1djd

— ANZUP (@ANZUPtrials) November 6, 2019

.@NICEComms has been busy with announcements today, rejecting Astellas’ #Xospata for a certain type of acute myeloid leukaemia (AML) and querying evidence for MSD's #Keytruda in head and neck cancer https://t.co/vFcLhQXJnT

— pharmaphorum (@pharmaphorum) January 15, 2020

MSD acquires Takeda’s Dunboyne manufacturing facility https://t.co/zOsjPUDhHN

— Silicon Republic (@siliconrepublic) August 10, 2020

MSD buys Takeda biologics medicines plant in Dunboyne https://t.co/IflH6PU1MF via @IrishTimesBiz

— Irish Times Business (@IrishTimesBiz) August 7, 2020

MSD to takeover Takeda's Dunboyne facility https://t.co/ACUOaUBlOd

— RTÉ Business (@RTEbusiness) August 7, 2020

This is a very welcome announcement from MSD and Takeda. https://t.co/C6aqYapp57

— Martin D Shanahan (@MartinDShanahan) August 7, 2020

Takeda acquired Tim Clackson's prev company, ARIAD, in '17 for $5.2 Billion. He had originally joined ARIAD in 1994. In addition to Takeda & Merck/MRL, German Merck's M Ventures & Ipsen's venture fund are also corporate VCs that invested in the B round. They moved 2 Waltham, MA https://t.co/OxT4HM5RxL

— Pearl Freier (@PearlF) March 2, 2020

Takeda & Merck (MRL Ventures) r 2 of the investors in #CambMA-based immuno-oncology Xilio Therapeutics fka Akrevia. $100.5M B. Originally launched by @atlasventure & F-Prime. CEO is @OtherReneRusso & Tim Clackson is Prez & EVP R&D.MRL Ventures @dud3k BOD https://t.co/JaUnc6UUXD

— Pearl Freier (@PearlF) March 2, 2020

Takeda, Merck invest in cancer startup's Xilio Therapeutics $100M Series B round – Bizwomen https://t.co/GBIVu54ivm #venturecapital #earlystageinvestors #angelinvestors #startups

— Red Trait Ventures (@RedTrait) March 4, 2020

PharmaScrip: Executives On The Move: Exits From Takeda Vaccines And Novartis Institutes To CMO Positions And Board Changes At Merck & Co. https://t.co/1Ah2xcjDQI #PharmaScrip https://t.co/3BT9hqerzu pic.twitter.com/ON8dj4Klug

— ZorgNL (@zorgnl) February 13, 2020

Impact of COVID-19 on Colorectal Cancer Therapeutics Market Latest trending report is booming globally by Top Leading Players Taiho Pharma, Merck KGaA, Amgen, Takeda https://t.co/Xud5IlkmE0

— mednetnews (@mednetnews) October 17, 2020

Colorectal Cancer Therapeutics Market 2020-2026 | Comprehensive Study COVID19 Impact Analysis | Worldwide Key Players: Taiho Pharma, Merck KGaA, Amgen, Takeda, Roche, etc. https://t.co/rJMqyCbJPm

— mednetnews (@mednetnews) September 5, 2020

Global Innovative Drug Market Expected to Reach highest CAGR: Pfizer,Gilead Sciences,Johnson & Johnson,Roche,AbbVie,Sanofi,Amgen,Novartis,Merck & Co. (MSD),GlaxoSmithKline (GSK),Bayer,Takeda,AstraZeneca,Novo Nordisk https://t.co/An4NCt3fo9

— @ReportsandMarkets (@ReportsMarkets) October 13, 2020

#VaccinesEurope represents drugmakers including #AstraZeneca, #GlaxoSmithKline, #Janssen (which belongs to Johnson & Johnson), #Merck, #Novavax, #Pfizer, #Sanofi, #Takeda, #Abbott and #CureVac. Covid-19 vaccine makers #LobbyEU for #LegalProtection.https://t.co/FNImlmq8yE

— Riikka Kevo (@riikka_kevo) August 26, 2020

Lipid Metabolism Disease Drug Market Latest updates and Coronavirus (COVID-19) Impact on Global Market in 2020-2029 Merck, Takeda Pharmaceutical and Novartis – The Loop 21 https://t.co/xazRpkLaZ2

— Dr Jitesh Arora (@drjitesharora) July 29, 2020

Who would want a simple solution?

"thank the leadership of AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eisai, Eli Lilly, Evotec, Gilead, GlaxoSmithKline, Johnson & Johnson, KSQ Therapeutics, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda, and Vir"https://t.co/V20z6DAu2U

— sandeep chakraborty (@sanchak74) June 12, 2020

Global #pharmaceuticals unprecedented collaboration in the search for effective #COVID19 therapies. IFPMA press conference on 30 April 2020 with key speakers across MSD, Takeda, CSL, Pfizer, AstraZeneca, Sandoz and Merck.https://t.co/Blg8sI0uHX @IFPMA @ThomasCueni @MedicinesAus

— Rozalina Sarkezians (@RozalinaRS) May 1, 2020

Pray to Merck, Pfizer, Sanofi, Takeda, J&J, Lilly. Pray to all the start up biotechnology firms throughout the world. Pray to science. An imaginary friend in the sky will not help you. https://t.co/jGz1Ga4fID

— The Grackle ☠ (@LanceMa89524580) March 20, 2020

Takeda, Merck invest in Waltham cancer startup's $100M round https://t.co/KOtqmEQWpy

— Matthew Liptak (@mattliptak) March 2, 2020

Global Drugs for Lipid Metabolism Disease Market 2020 Raises During Pandemic Phase 2021 | Merck, Novartis, Takeda Pharmaceutical – Best News Monitoring https://t.co/6mUdaMY12P

— Dr Jitesh Arora (@drjitesharora) July 29, 2020

Skyhawk Therapeutics, one of GGC's first portfolio companies, recognized by BostInno as one of the 20 Boston Startups to Watch in 2020! Great progress on HUGE dollar contracts with Celgene / Bristol-Myers Squibb, Biogen, Merck, Takeda and Genentech. https://t.co/cktw5pUivN

— Good Growth Capital (@goodgrowthvc) December 23, 2019

U.K. イギリス Vol.30（pharmaceutical corporations 製薬会社）

All the below link and tweets are in English.

取り急ぎ以下貼っておきます。

UK Vol.169 (pharmaceutical corporations: AstraZeneca)

追加（本日までのツイート）

White blood cells produce antibodies in response to infection. Over 25 years, @croweje and @VUMC_Vaccines have pioneered techniques for isolating human “monoclonal” antibodies to neutralize pathogenic viruses with a laser-like focus. #COVID19 @AstraZeneca https://t.co/yomHmoGDpW

— VUMC Insights (@VUMC_Insights) October 14, 2020

Read Heather Macdonald-Tait’s account of what motivated her to volunteer for a trial of the #COVID19 vaccine developed by @UniofOxford and @AstraZeneca, and her experiences so far: https://t.co/LYpCFkxVbE

— Gavi, the Vaccine Alliance (@gavi) October 14, 2020

US Signs Deal With @AstraZeneca to Develop, Make #COVID19 Antibody Treatment

Learn more: https://t.co/oJncXqIEB1 pic.twitter.com/Bb8LWIbq5o

— AJMC (@AJMC_Journal) October 10, 2020

We’re partnering w/ @JPEOCBRND & @AstraZeneca under #WarpSpeed on clinical trials and large-scale manufacturing of a monoclonal antibody therapeutic to prevent #COVID19. With @US_FDA authorization, the doses could be used to help fight the pandemic https://t.co/ugxfm9LQyw pic.twitter.com/TUHAQMtLNU

— BARDA (@BARDA) October 9, 2020

.@BARDA, @JPEOCBRND & @AstraZeneca are working together at #WarpSpeed on clinical trials and large-scale manufacturing of a medicine to prevent #COVID19. The government will own these first doses and can make them available with authorization from @US_FDA. https://t.co/7LP5tF4rCf pic.twitter.com/924YcaCEvW

— ASPR (@PHEgov) October 9, 2020

Due to a month-long halt of the trial imposed by #US regulators investigating potential side-effects, volunteers have only been given one dose of the vaccine #COVID19 #Oxford @AstraZeneca https://t.co/NYt8lWVaHM

— Arab News (@arabnews) October 7, 2020

US Govt has awarded $486 million to @AstraZeneca PLC to develop & secure supplies of up to 1 lk doses of #COVID19 antibody treatment, a similar class of drug that was used in treating President #Trump: US Health Dept@realDonaldTrump @AstraZenecaUS pic.twitter.com/ahDVDSne3n

— ET NOW (@ETNOWlive) October 12, 2020

The U.S. government and @AstraZeneca have teamed up to develop 100,000 doses of #COVID19 antibody treatments for high-risk populations, with the possibility for the U.S. to acquire an additional 1,000,000 doses in 2021.

Learn more, via @CNBC https://t.co/A22Y0hOkLp

— Solomon McCown & Cence (@solomonmccown) October 12, 2020

A #COVID19 #vaccine trial by @UniofOxford and @AstraZeneca was paused last month due to a reported side effect in a patient.
But how common is pausing a vaccine trial? How does the trial resume? Do vaccine companies really treat safety seriously?@Dr_Banika explains: pic.twitter.com/3nkwwA9pLy

— hospital research (@hosp_research) October 13, 2020

.@AstraZeneca received $1.2 BILLION to develop a #COVID19 vaccine from the US government. But that didn't satisfy their greed.

Since their Texas-sized payday, the company announced price hikes on many of their products TWICE. https://t.co/GdaTXQnzJk

— Texans For Affordable Rx (@TX4AffordableRx) October 8, 2020

After @Novartis & @AstraZeneca J&J puts on hold it’s #COVID19 trial due to unexplained illness in participant… All this isn’t surprising. Beyond the hype, reality of #clinicaltrials catches up with us… It’s a long, risky & unpredictable endeavor. https://t.co/YWV56CNFqA

— Amine Korchi MD (@AmineKorchiMD) October 13, 2020

#US, @AstraZeneca sign pact for #COVID19 antibody treatment used to treat #Trump https://t.co/ulVrswN2gD | #pharma #pharmanews #IndiaIncfightsCovid19

— ExpPharma (@ExpPharma) October 11, 2020

Let's talk about some real COVID19 drugs for a moment. The one drug that really helped me in my own COVID19 infection was Symbiocort by @AstraZeneca. I already had some at home for my asthma: my doc in Canada had given me a free sample he'd gotten from his drug rep. 1/ https://t.co/AKb6IAi6Y2

— Shawn Wenzel (@shawnwenzel) October 8, 2020

“Front-runners @Pfizer and @AstraZeneca say they have no plans to do challenge studies. Other #vaccine makers like @JNJNews are eyeing them cautiously… @moderna_tx has started manufacturing a strain of the virus that could be used for challenge studies…” #COVID19 #compliance https://t.co/McIgobW16i

— Mark Warner (@MAAWLAW) October 13, 2020

US backs @AstraZeneca #COVID19 antibody drug with $486M in funding. Read more at: https://t.co/tsxzEXmJIv

—#biomanufacturing #biopharma #pharmaceutical #pharma #vaccine pic.twitter.com/feSd63P3Qm

— American Biomanufacturing (@BioMfg) October 13, 2020

Pharma continue to hold the reins. "MoU between @AstraZeneca and a Brazilian manufacturer, which has been seen by @financialtimes, defines the “Pandemic Period” as ending on July 1 2021." #COVID19
https://t.co/2iBoiiC4Gz

— Shailly Gupta (@Shaillytweeting) October 7, 2020

Mergers & Acquisitions explores 5 ways the #coronavirus is changing #dealmaking, as pharmaceutical companies such as @sanofi and @astrazeneca scramble to develop vaccines, diagnostic tools and treatments https://t.co/wvz94Eh9iZ

— Mergers&Acquisitions (@TheMiddleMarket) October 7, 2020

EMA begins real-time review of @AstraZeneca's #COVID19 vaccine: https://t.co/lHiEaN1tfE @EMA_News #clinicaltrials #COVID #CoronaVirus #Vaccine

— Teckro (@teckroofficial) October 9, 2020

Cambridge trio accelerate COVID-19 initiatives https://t.co/cLkjZ8M5oH @AstraZeneca @GileadSciences @sanofi @UniofOxford #COVID19 #coronavirus #Remdesivir pic.twitter.com/pfmZB60RxB

— Business Weekly (@businessweekly) October 8, 2020

Great news. The two vaccines for COVID-19: One is being developed by the company @AstraZeneca, Cambridge, UK, in collaboration with the University of Oxford, the other by @BioNTech_Group, Mainz, Germany, in collaboration with @pfizer, NY, USA. #COVID19. By @ChemistryViews https://t.co/sNXkzsF82d

— Química y Sociedad (@ForoQyS) October 8, 2020

Staffordshire is set to receive 600,000 doses of coronavirus vaccination from as early as November! It's great to hear that a vaccine to combat #COVID19 is being manufactured @KeeleUniversity following an agreement between @CobraBiologics & @AstraZeneca UK https://t.co/eXw21WRYO5

— Croft Architecture (@CroftArchitects) October 8, 2020

AstraZeneca eligible for provisional registration of Covid-19 vaccine after ruling by Therapeutic Goods Administration. News via @CanberraIQ for your daily news digest. For a free trial: https://t.co/jLzrWSAOYG @TGAgovau @AstraZeneca #COVID19 #pandemic https://t.co/hGDtvFgyl5

— Canberra IQ (@CanberraIQ) October 11, 2020

A vaccine to treat COVID-19 globally is imminent but its likely effectiveness has been laid bare. @AstraZeneca @pfizer @JennerInstitute #COVIDVaccine #Vaccine https://t.co/iir1So9X2O

— The CEO Magazine (@TheCEOMagazineG) October 14, 2020

ツイッター検索で上記製薬会社及び Japan や日本の5製薬会社各社名を入れて出て来たもの

We are thrilled to be building on our long-standing heritage in breast cancer through our collaboration announced today with Daiichi Sankyo. To learn more about why we believe pioneering new treatments in this area are so important, click here: https://t.co/1Haz3gHlud pic.twitter.com/pkXJnovNgz

— AstraZeneca (@AstraZeneca) March 29, 2019

AstraZeneca-Daiichi Sankyo's gastric cancer drug wins approval in Japan @AstraZeneca #daiichisankyo https://t.co/n2VmONPEKA pic.twitter.com/oaN0SVZtB1

— Market Intelligence: Healthcare (@SPGMIHealthcare) September 28, 2020

AstraZeneca to pay Daiichi Sankyo $1B up front in #cancer drug collaboration @AstraZeneca @DaiichiSankyo #dealmaking https://t.co/HjFewEzOS1 pic.twitter.com/8gdC72bRiM

— Market Intelligence: Healthcare (@SPGMIHealthcare) July 27, 2020

AstraZeneca-Daiichi Sankyo drug gets US FDA breakthrough tag for lung #cancer @AstraZeneca #enhertu https://t.co/8JOmhiH3dh pic.twitter.com/Gg2Bcxhuat

— Market Intelligence: Healthcare (@SPGMIHealthcare) May 18, 2020

COVID-19 Vaccine: AstraZeneca AZD1222 phase 1/2 trials to begin in Japan @AstraZeneca,@DaiichiSankyo #astrazeneca #astrazenecanews #clinicaltrial #coronavirus #covid-19 #coronavirusvaccine #azd1222 #daiichisankyo #jcrpharma https://t.co/ndeokzCfcI

— Medical Dialogues (@medicaldialogs) September 6, 2020

AstraZeneca, Daiichi Sankyo gets USFDA Breakthrough Therapy status for lung cancer drug Enhertu @AstraZeneca,@DaiichiSankyo #astrazeneca #cancer #enhertu https://t.co/6pyPdJqecP

— Medical Dialogues (@medicaldialogs) May 19, 2020

.@AstraZeneca has agreed a global development and #commercialization deal with @DaiichiSankyoUS, worth up to $6 billion for the Japanese #pharma. The deal centers on Daiichi Sankyo’s TROP2-directed antibody drug conjugate DS-1062 https://t.co/VC2DGKjyWP pic.twitter.com/BA6qSTSzWf

— CHEManager International (@CHEManager_EU) August 6, 2020

.@AstraZeneca has agreed to develop .@DaiichiSankyoUK Phase I cancer antibody drug conjugate DS-1062 worldwide except Japanhttps://t.co/jeq0LARzDm
DS-1062 is a trophoblast cell-surface antigen 2 -directed ADC for non-small cell lung cancer and triple negative breast cancer.

— Decipher Analytics (@DecipherAnalyt2) July 30, 2020

@AstraZeneca bets up to $6 billion on new Daiichi cancer drug.https://t.co/CvDOIuBdVj

— TheNewsPanels (@TheNewsPanels) July 29, 2020

A look at some of the success factors behind yesterday's mammoth ADC deal with @AstraZeneca #pharma #biotech

Oncology Deal-Making The Daiichi Way https://t.co/NPnpZgejGG

— Ian Haydock (@ScripIanHaydock) July 28, 2020

AstraZeneca bets $1B on Daiichi rival to Immunomedics' Trodelvy | @AstraZeneca @ImmunomedicInc @Pfizer @DaiichiSankyo #pancsm #lungcancer #cancer #breastcancer #Biotech #NewJersey https://t.co/QV27IJeUjW

— Aspen Biosciences (@aspenbio) July 27, 2020

AstraZeneca & Daiichi Sankyo enter collaboration to develop and commercialise new ADC https://t.co/c3BBGtcTba @AstraZeneca @EUdaiichisankyo More European life science business news at [LSE] at https://t.co/df6Gi5dTPT pic.twitter.com/E3kdckFgzF

— [iito] Life Science (@iitoLifeScience) July 27, 2020

.@AstraZeneca pays $1B upfront & ~$5B milestones to codevelop DS-1062 w/ @DaiichiSankyo outside of Japan

TROP2-directed DXd #antibody-drug conjugate is currently in Ph1 #clinicaltrials vs #NSCLC & #TNBC https://t.co/pXa46t3W6S #immunooncology #ADC #LungCancer #BreastCancer pic.twitter.com/jjm8bKCcyb

— DDNews Online (@DDNewsOnline) July 27, 2020

@AstraZeneca strengthens Daiichi Sankyo partnership with new development of a novel antibody drug conjugate (ADC) for the treatment of a number of multiple tumours which express the cell-surface glycoprotein TROP2https://t.co/aUefWC4btv vía @pmlivecom

— Jose Antonio Gasquet (@jagasquet) July 27, 2020

.@AstraZeneca & Daiichi have also been in talks over the supply of the British company's potential coronavirus vaccine in Japan.https://t.co/k1kqx6uYuL

— CNBC-TV18 (@CNBCTV18Live) July 27, 2020

.@AstraZeneca could pay up to $6 billion to #Japan's Daiichi Sankyo to develop and market a type of targeted cancer treatment in the second multi-billion dollar #cancer drug collaboration between the two companies.https://t.co/5CoLjHOdY9

— The Jerusalem Post (@Jerusalem_Post) July 27, 2020

AstraZeneca Collaborates with Daiichi Sankyo to Evaluate the Combination of Patritumab Deruxtecan (U3-1402) + Tagrisso for EGFR-Mutated Non-Small Cell Lung Cancer @AstraZeneca @DaiichiSankyoUS https://t.co/GegHhaEVis pic.twitter.com/y5XRj56gWY

— PharmaShots – Incisive news in 3 shots (@Pharmashot) August 7, 2020

Daiichi Sankyo in Talks with AstraZeneca for the Supply of AZD1222 to Combat COVID-19 in Japan @AstraZeneca @DaiichiSankyo https://t.co/xcsgbutsPz pic.twitter.com/T6p9mCQ6YE

— PharmaShots – Incisive news in 3 shots (@Pharmashot) June 29, 2020

AstraZeneca and Daiichi Sankyo Provide Updates of Enhertu (fam-trastuzumab deruxtecan-nxki) in HER2-Positive Metastatic Colorectal Cancer and HER2-Mutant Non-Small Cell Lung Cancer #ASCO20 @AstraZeneca @ASCO https://t.co/ukMWYKFZfo pic.twitter.com/SjMNX4tMH6

— PharmaShots – Incisive news in 3 shots (@Pharmashot) June 1, 2020

AstraZeneca Signs a Worldwide Development and Commercialization Agreement with Daiichi Sankyo for $6.9B @AstraZeneca
https://t.co/zV274HcNZW

— PharmaShots – Incisive news in 3 shots (@Pharmashot) April 1, 2019

One of @AstraZeneca's most decisive moves last year came when it signed a multi-billion dollar deal with @EUdaiichisankyo, focused on just one breast cancer drug. We spoke with Daiichi's @GillesJAGallant about the future plans for the drug https://t.co/C4VAEammCR pic.twitter.com/6NeXkiU5Kf

— pharmaphorum (@pharmaphorum) January 30, 2020

Results from a piviotal study of @AstraZeneca and Daiichi Sankyo’s trastuzumab deruxtecan, showed that women with breast cancer who had not responded to around six prior treatment courses saw no further progression for a median of 16.4 months https://t.co/TL1sLOmgf6

— pharmaphorum (@pharmaphorum) December 12, 2019

AstraZeneca, Daiichi Sankyo get Orphan Drug Designation for gastric cancer drug Enhertu @AstraZeneca #astrazeneca #enhertu #usfda #daiichisankyo #gastriccancer #trastuzumabderuxtecan https://t.co/ofKbiL4T8M

— Medical Dialogues (@medicaldialogs) May 25, 2020

Rare disease: Enhertu of @AstraZeneca and Daiichi Sankyo now with Orphan Drug Designation in the US for treatment of gastric cancer https://t.co/IZqqD1DNTf #gastricCancer #rarediseases #cancers #oncology pic.twitter.com/npY2FpPoZF

— EuropaWire (@europawire) May 22, 2020

From the Center for Biosimilars, @AstraZeneca + Daiichi-Sankyo win @US_FDA OK for #trastuzumab antibody conjugate #Enhertu https://t.co/s2E3s6bSr8

— AJMC-Oncology (@EBOncology) December 23, 2019

FDA accepts BLA from AstraZeneca and Daiichi for targeted chemotherapy@AstraZeneca @DaiichiSankyo #oncologydrugs #targetedchemotherapy https://t.co/NB0YHsLwUI

— Pharma Tech Focus (@PharmaTechFocus) October 18, 2019

AstraZeneca and Daiichi Sankyo sign $6.9bn cancer drug development deal @AstraZeneca @EUdaiichisankyo #cancerdrugdevelopment #bigpharmadealts https://t.co/lWXBRDSHS8

— Pharma Tech Focus (@PharmaTechFocus) March 29, 2019

Full house at AstraZeneca Exchange event at the Judge Business School, University of Cambridge. Fascinating insight to the recent AZ/Daiichi Sankyo deal from the people who made it happen @AstraZeneca @CambridgeJBS pic.twitter.com/CaN7n8PAw2

— Milner Institute (@TheMilnerInst) July 3, 2019

@AstraZeneca and Daiichi's #HER2 ADC hits goal in pivotal trial https://t.co/E0rhjfKnGX

— Miles Collier (@MilesCollier) May 8, 2019

.@AstraZeneca has signed a $6.9bn collaboration with Daiichi Sankyo to co-partner on cancer drug DS8201. Read full note here @LiberumToday #aim #shares https://t.co/R2styv9Pxs pic.twitter.com/trsEc3uZiW

— Research Tree (@research_tree) April 5, 2019

@AstraZeneca signs $6.9B deal with Daiichi Sankyo for #cancertherapy #healthcare #news https://t.co/kw2IhwuIBT

— Healthcare Opportunities (@HealthcareOppo1) April 3, 2019

.@AstraZeneca will pay up to $6.9 billion in #cancer drug deal with Daiichi and more for #pharma #marketers to know. #drugprices #DTC $JNJ $AZN $GILD https://t.co/CIJqaYE6LJ pic.twitter.com/j6VKJgbvgW

— MM+M Magazine (@MMMnews) April 1, 2019

.@AstraZeneca and Daiichi Sankyo brought us a huge deal last night. We worked on the Top 20 #cancer deals with @JohnCendpts at @endpts with data from @DealForma $AZN https://t.co/HJjEAS19Gz

— Chris Dokomajilar (@ChrisDoko) March 29, 2019

.@AstraZeneca sought to buy Japan's Daiichi Sankyo last year https://t.co/BQ6IFBwu8l pic.twitter.com/s933R4Glvb

— The Business Times (@BusinessTimes) August 31, 2017

#AZN £85.95 #AI #PHARMA $AZN & Daiichi Sankyo enter collaboration to develop & commercialise new #antibody drug✅
Calquence recommended for approval in the EU for chronic #leukaemia✅
Imfinzi recommended for approval in the EU for small cell lung #cancer✅https://t.co/pRRm18hjeI pic.twitter.com/uHD3PLkvay

— Peter Higgins (conkers) (@conkers3) July 27, 2020

#AZN-4% £62.05 $3.5Bn #Placing & collaboration w/ Daiichi Sankyo for #HER2 ADC #trastuzumab deruxtecan (DS-8201) w/ upfront payment of $1.35B, plus up to $5.55B include $3.8B for regulatory & other milestones, as well as $1.75B for sales-related milestones https://t.co/Lj8lTxIsdL pic.twitter.com/YmjCiZF2TR

— Peter Higgins (conkers) (@conkers3) March 29, 2019

AstraZeneca Resumes Clinical Study of its COVID-19 Vaccine in Japan @AstraZeneca https://t.co/l8IrrMu0oz pic.twitter.com/Wyn0BkNSKz

— PharmaShots – Incisive news in 3 shots (@Pharmashot) October 5, 2020

AstraZeneca and MSD’s Selumetinib Receive MHLW’s Orphan Drug Designation for Neurofibromatosis Type 1 in Japan @AstraZeneca @Merck https://t.co/azsnR93iP5 pic.twitter.com/34oe5UGj9p

— PharmaShots – Incisive news in 3 shots (@Pharmashot) June 30, 2020

.@AstraZeneca Plc said on Friday clinical trials of its experimental COVID-19 #vaccine resumed in Japan.https://t.co/enubUg9VQ6 pic.twitter.com/bSDa4lRQTp

— Arab News Japan (@ArabNewsjp) October 3, 2020

Major British drugmaker @AstraZeneca PLC said Friday that it has agreed with the Japanese government to launch negotiations on supplying #Japan with a #coronavirus vaccine currently under development with University of Oxford.https://t.co/OTrkWJzmHn pic.twitter.com/MYMrK1ZReE

— Arab News Japan (@ArabNewsjp) June 27, 2020

Japan's Prime Minister @AbeShinzo said Sunday that the country is in talks with pharmaceutical firms overseas to secure vaccines for the novel #coronavirus towards the end of the year.@AstraZeneca https://t.co/k41GZj2afH pic.twitter.com/hKODrfAh5O

— Arab News Japan (@ArabNewsjp) June 14, 2020

.@AstraZeneca resumes #COVID19 #vaccine trial in Japan, U.S. still paused. https://t.co/reQEFIZw5M

— A Voice For Choice Advocacy (@avoiceforchoice) October 2, 2020

https://twitter.com/moneycontrolcom/status/1311949554284023808

Kudos to @AstraZeneca whose Breztri Aerospher has become the first triple-combination therapy for #COPD in a pressurized metered-dose #inhaler device to be approved in Japan. https://t.co/9KlWUm8B8t #NoblePharma #GoNoble

— Noble (@NoblePharma) August 9, 2019

Latest newsletter highlights: VivaGel BV European & AU launch, $SPL’s 2nd @AstraZeneca agreement, VivaGel condom launch in Japan w/ @Okamototown & our DEP programs https://t.co/mOVSIwGRZ6 #ASX pic.twitter.com/jK9jN33tY9

— Starpharma (@Starpharma_ASX) July 1, 2019

#AstraZeneca Reports Approval Of #Tagrisso In #Japan https://t.co/yEwHkUDRvG @RTTNews @AstraZeneca #osimertinib #NSCLC

— Plexus Ventures (@PlexusVentures) August 22, 2018

In industry news: Lynparza Approved in Japan for BRCA-Mutated Metastatic #BreastCancer @AstraZeneca @Merck https://t.co/rYdVMDnSfm pic.twitter.com/GEOQrnCUeQ

— Mammary Cell News (@MammaryCell) July 6, 2018

What possibilities for business with the #EU #Japan free trade agreement? Highly relevant seminar in Stockholm today by @BusinessSweden and @SweMFA, with opening by @AnnLinde. @AstraZeneca @BabyBjornSweden @Virtusize @Kommerskoll pic.twitter.com/D9A92vi2tC

— Anna Stellinger (@AnnaStellinger) March 28, 2018

Inflammatory Intestinal Diseases Findings: Efficacy & Safety of Oral #Budesonide in Patients with Active #Crohn's Disease in Japan: A Multicenter, Double-Blind, Randomized, Parallel-Group Phase 3 Study #Crohns @AstraZenecaSE @AstraZeneca @S_Karger_Japan https://t.co/bejGi7Mmg5 pic.twitter.com/hZnd8trekI

— Karger Open Access (@KargerOpen) November 28, 2017

Our employees from around the globe did their bit for #EarthDay at the weekend, with teams from Serbia, to Japan & the US joining the #EarthDayCleanUp19. Find out more about our approach to environmental protection as part of our sustainability strategy: https://t.co/1wtTM2Z3xp. pic.twitter.com/N2xBB4hMvh

— AstraZeneca (@AstraZeneca) April 25, 2019

Did you know that we have committed to moving 100% of our vehicle fleet across Europe, North America & Japan to hybrid, plug-in or electric by 2025? This is one of the ways we are working to #ActOnClimate earning us a spot on the @CDP #CDPAList: https://t.co/1g9MJYeXD3 pic.twitter.com/1KbqbupS7C

— AstraZeneca (@AstraZeneca) February 25, 2019

https://twitter.com/BCCJapan/status/1193767882334687232
https://twitter.com/BCCJapan/status/1071924366328258560

Phase III and Phase II/III clinical trials studying immunization for #RSV disease prevention for all infants have launched in Japan. We are pleased to partner with @AstraZeneca in an effort to reduce the burden of #RSV worldwide. Learn more here: https://t.co/a7KpuD4M4Z pic.twitter.com/7ven9yqeHK

— Sanofi (@sanofi) October 11, 2019

Astrazeneca Pharma initiates the commercial launch of XIGDUOA XR tablets in India. XIGDUOA XR is a product of @AstraZeneca Group approved in 61 countries including US, EU & Japan. It is used to treat type 2 diabetes mellitus pic.twitter.com/JqEBOjh5dJ

— CNBC-TV18 (@CNBCTV18Live) February 12, 2018

.@AstraZeneca enters agreement with Kyowa Hakko Kirin to commercialise antibody to treat asthma/COPD in Japan http://t.co/3yBVniGTW0 #pharma

— SartoriusRoyston (@TAPBiosystems) July 18, 2015

Grünenthal to Acquire AstraZeneca’s European rights to Nexium & Global (ex US & Japan) Rights to Vimovo for up to $922m https://t.co/uAVjxWY3IX @grunenthalgroup @AstraZeneca More European life science business news at [LSE] at https://t.co/8to5cxePG5 pic.twitter.com/lceOUo8wHH

— [iito] Life Science (@iitoLifeScience) October 30, 2018

AstraZeneca: Tagrisso Approved in Japan for 1st-line EGFR-mutated NSCLC https://t.co/FRUMYxZIYx @AstraZeneca More UK & Irish life science business news at [LSE] at https://t.co/ShKV2svWTv pic.twitter.com/XDjdQn2XTd

— [iito] Life Science (@iitoLifeScience) August 21, 2018

#AZN £63.74 After positive news: #Calquence trial✅#Lynparza approved in the #EU✅#Bevespi #Aerosphere approved by the #Japanese MH✅
Lynparza approved in #Japan✅
Breztri Aerosphere (PT010) approved in Japan✅https://t.co/pRRm18hjeI #COPD #PHARMA #AI pic.twitter.com/z0rSyl0eqz

— Peter Higgins (conkers) (@conkers3) June 19, 2019

#AZN £59.90 #Tagrisso approved in #Japan for 1st-line treatment of EGFR-mutated non-small cell lung #cancer.
1st-line Tagrisso offers a potential new standard of care for Japanese lung cancer patients✅https://t.co/C8ZDZK9cuV #PHARMA #BIOTECH #BIOPHARMA #MEDTECH #AI #ML #SCIENCE pic.twitter.com/vCp7Y2yiWn

— Peter Higgins (conkers) (@conkers3) August 21, 2018

#AZN +2% £53.59$AZN Regulatory submission in #Japan for #Forxiga in type-1 #diabetes✅ https://t.co/TLiZLg7L6I

US regulators finally approve @AstraZeneca' potential blockbuster #LOKELMA drug✅https://t.co/GDxPfuUR0D #PHARMA #BIOTECH #INVESTING #QARP pic.twitter.com/0P5FEP3J0E

— Peter Higgins (conkers) (@conkers3) May 21, 2018

#AZN+1% £50.36 @DigitalLookNews #AstraZeneca gets approvals for #Fasenra & #Lynparza in #Japan✅Lynparza is the first poly ADP-ribose polymerase (PARP) inhibitor to be approved in Japan✅ https://t.co/ErNbKkH0YE #bronchial #asthma #COPD $AZN #PHARMA #BIOTECH #BIOPHARMA #MEDTECH pic.twitter.com/QLyA8r41IC

— Peter Higgins (conkers) (@conkers3) January 19, 2018

.@AstraZeneca Q1 Results http://t.co/eYQpCrJ12W Growth platforms (Brilinta, diabetes, respiratory, Emerging Markets & Japan) +13% to $3.4Bn

— Peter Higgins (conkers) (@conkers3) April 24, 2015

#DRG epidemiology report estimates more than 35,000 newly diagnosed cases of #chroniclymphocyticleukemia across the United States, Western Europe and Japan. Detailed global reports available now @DRGinsights #CLL #leukemia chronic #lymphocyticleukemia @AstraZeneca https://t.co/c93A2A45xs

— DRG Epidemiology (@DRG_Epi) December 2, 2019

#DRG epidemiology report estimates more than 3.5 million people affected with #hyperkalemia across the United States, Western Europe and Japan. Detailed report available now @DRGinsights #kidney #KidneyWk #chronickidneydisease @AstraZeneca https://t.co/PV3qywDoqv

— DRG Epidemiology (@DRG_Epi) November 18, 2019

#DRG epidemiology report estimates over 35,000 newly diagnosed cases of #chroniclymphocyticleukemia across the United States, Western Europe and Japan. Detailed global reports available now @DRGinsights #CLL #leukemia #lymphocyticleukemia #BloodCancerAwarenessMonth @AstraZeneca https://t.co/a86N2RqLkg

— DRG Epidemiology (@DRG_Epi) September 11, 2019

More than 7000 newly diagnosed #ovariancancer cases have #BRCA #mutations across the United States, Western Europe and Japan. Watch this space for more updates on #DRG global epidemiology data @DRGinsights #ovarian #cancer #biomarkers #tumors #genetictesting @AstraZeneca https://t.co/X2aYXDRkqQ

— DRG Epidemiology (@DRG_Epi) September 3, 2019

#DRG epidemiology report estimates more than 35,000 newly diagnosed cases of #chroniclymphocyticleukemia across the United States, Western Europe and Japan. Detailed global reports available now @DRGinsights #CLL #leukemia chronic #lymphocyticleukemia @AstraZeneca https://t.co/dIbsLkOrVa

— DRG Epidemiology (@DRG_Epi) August 22, 2019

More than 3.5 million people are affected with #hyperkalemia across the United States, Western Europe and Japan. Follow us for more updates on #DRG epidemiology data on #hyperkalemia #CKD @DRGinsights @AstraZeneca #KidneyWk https://t.co/xOVhUSaqVL

— DRG Epidemiology (@DRG_Epi) October 25, 2018

#DRG reports more than 10 million cases living with #Alzheimers across the United States, Western Europe and Japan https://t.co/r92nrjx1mO @DRGinsights @AstraZeneca https://t.co/xk3LFosS3Q

— DRG Epidemiology (@DRG_Epi) August 3, 2018

Thanks to our @ANZUPtrials #bestofGUoncology #ANZUPGU19 sponsors – @IpsenGroup Astellas Oncology @AstraZeneca @MSD_Aus pic.twitter.com/WtTfQE1djd

— ANZUP (@ANZUPtrials) November 6, 2019

Thanks also to our #APCCC APAC Satellite Symposium sponsors Astellas @AstraZeneca @IpsenGroup @JanssenANZ and Tolmar #APCCCinAPAC18 pic.twitter.com/AnrhNOAxuu

— ANZUP (@ANZUPtrials) February 23, 2018

.@MeetingsShow’s healthcare education speakers to include @AstraZeneca and Astellas: http://t.co/EtOBMyb9Q5 #TMS15 pic.twitter.com/xlnTvYk3fr

— Soaring Worldwide (@SoaringWW) June 16, 2015

United States Shingles Vaccine Market @SanofiPasteur,@GlaxoSmithKline,@Merck,@Pfizer,@AstraZeneca,@Mitsubishi,@EmergentBiosolutions,@Astellas,@Valneva,@Seqirus,@BavarianNordic,@Sinovac,@Panacea,@BharatBiotech #shingles #zoster #vaccine https://t.co/DIBnqocTp0 via @dpiresearch

— DPI Research (@DPIResearch) October 14, 2020

Vaccines Market Booming Worldwide With Leading Players https://t.co/yVs3yTmMC8 @SanofiPasteur,@GlaxoSmithKline,@Merck,@Pfizer,@AstraZeneca,@Mitsubishi,@EmergentBiosolutions,@Astellas,@Valneva,@Seqirus,@BavarianNordic,@Sinovac,@Panacea,@BharatBiotech

— DPI Research (@DPIResearch) September 28, 2020

United States Influenza Vaccines Market Forecast 2020 – 2027 https://t.co/ovFvfMYYfI @SanofiPasteur,@GlaxoSmithKline,@Merck,@Pfizer,@AstraZeneca,@Mitsubishi,@EmergentBiosolutions,@Astellas,@Valneva,@Seqirus,@BavarianNordic,@Sinovac,@Panacea,@BharatBiotech

— DPI Research Official (@dpi_research) August 28, 2020

I just published US Influenza(Flu) Vaccine Market https://t.co/I0te2HEkCW @SanofiPasteur,@GlaxoSmithKline,@Merck,@Pfizer,@AstraZeneca,@Mitsubishi,@EmergentBiosolutions,@Astellas,@Valneva,@Seqirus,@BavarianNordic,@Sinovac,@Panacea,@BharatBiotech

— DPI Research Official (@dpi_research) August 27, 2020

Analyst Keshalini Sabaratnam @Pharma_GD on the #sales #forecast for @Merck and #Otsuka 's #Keytruda (pembrolizumab) projected to be top drug by 2023 and what does this mean for their #contractmanufacturers #CDMO #CMO @AstraZeneca @BoehringerDE https://t.co/R6Wmwcm2Qb

— GlobalData PharmSource (@PharmSource) October 2, 2019

#Innovation #Index #Pharma @baxter_intl @Celgene #Otsuka @AstraZeneca @Roche @Novartis… https://t.co/zzzaGWoCii pic.twitter.com/sbAEuYm54a

— Biotechin.asia (@biotechinasia) April 10, 2016

AstraZeneca and Eisai make EMA demands:
The European Medicines Agency will relocate from the UK in light of Brexit. https://t.co/plD7JJnH1z @AstraZeneca #Eisai #EMA @EMA_News #Brexit #medicine #health #Lifesciences

— LifeSciencesIPReview (@LifeSciencesIPR) January 10, 2018

.@AstraZeneca and Eisai support continued @EMA_News oversight of drugs and safety on both sides of the Channel. Minimum demand is “mutual recognition” of medicines standards. #Brexit https://t.co/2RNHEIPPMA

— RegMedNet (@RegMedNet) January 9, 2018

On #WorldNTDDay we celebrate our industry partnerships to #beatNTDs including the innovative Drug Discovery Booster to discover new drugs with @abbvie @AstellasUS @AstraZeneca @bmsnews @Eisai_SDGs @merckgroup Shionogi & @TakedaPharma. pic.twitter.com/j4Xgs60vO2

— Drugs for Neglected Diseases initiative (@DNDi) January 30, 2020

DNDi partners with Eisai, Shionogi, Takeda, and @AstraZeneca to find new treatments for #Chagas and #leishmaniasis http://t.co/ZA64pVAEhE

— Drugs for Neglected Diseases initiative (@DNDi) May 29, 2015

Huge thanks to @wellcometrust for having confidence in us. Terrific to be working in partnership with @turinginst to combine scientific excellence with commitment to improve the working environment for trainees with @NHSDigital @eisai @gsk @AstraZeneca @Microsoft @intel @iqvia https://t.co/bjIYmMhDH0

— Andrew Morris (@profadmorris) September 16, 2019

Excellent dialogue b/t #GlobalHealth leaders, philanthropic pharm. cos. @AstraZeneca @Eisai and NGOs @DND about partnerships to #CombatNTDs pic.twitter.com/jQwl8S8XAP

— MAP International (@mapintl) October 27, 2017

The 2020 Pharmaceutical Innovation and Invention Index is live at @FortuneMagazine: https://t.co/dLQhy8vDMF
2020 Innovation Index
1 @Roche
2 @abbvie
3 @Novartis
3 @VertexPharma
5 @LillyPad
6 @AstraZeneca
7 @AlexionPharma
8 @Merck
9 Shionogi
10 @JNJNews
10 @Regeneron

— Mike Rea, IDEA Pharma (@ideapharma) April 6, 2020

.@purduepharma and Shionogi take on @AstraZeneca, @Valeant in opioid-induced constipation. https://t.co/KaqgT4sAnO #DrugApproval $AZN $VRX pic.twitter.com/LlFIXx79wf

— FiercePharma (@FiercePharma) March 24, 2017

Vaccines Market Booming Worldwide With Leading Players @SanofiPasteur @GSK @Merck @Pfizer @AstraZeneca @Mitsubishi @emergentbiosolu @AstellasPharma @Valneva @Seqirus @CSLLimited @BavarianNordic @Sinovac @PanaceaBiotec @Dynavax @Grifols https://t.co/G6av4krbos via @dpiresearch

— DPI Research (@DPIResearch) October 5, 2020

Check out my latest article: Flu Vaccines Market Worth $7.5bn by 2027
https://t.co/ZbzwVCpnrq via @LinkedIn @SanofiPasteur @GSK @Merck @Pfizer @AstraZeneca @Mitsubishi @EmergentBioSolutions@AstellasPharma @Valneva @Seqirus @CSLLimited @BavarianNordic @Sinovac @PanaceaBiotec

— DPI Research (@DPIResearch) October 7, 2020

https://t.co/6rgVwPyvqg @SanofiPasteur @GSK @Merck @Pfizer @AstraZeneca @Mitsubishi @EmergentBioSolutions@AstellasPharma @Valneva @Seqirus @CSLLimited @BavarianNordic @Sinovac @PanaceaBiotec @Dynavax @Grifols

— DPI Research (@DPIResearch) October 11, 2020

#ImaginAb joins with #AstraZeneca, #Pfizer and #Takeda to develop #tumourimaging #tech https://t.co/ccUgDG0BiV via @pharmaphorum @AstraZeneca @pfizer @TakedaPharma #technology #immunotherapies

— Plexus Ventures (@PlexusVentures) October 14, 2019

“@Novavax has signed similar deals with the UK, India, the Czech Republic, South Africa & Japan to supply doses of the potential #vaccine… [The Canadian government] is also in the final stages of negotiations with drug firm @AstraZeneca…” #COVID19 https://t.co/1qusqAiqJQ

— Mark Warner (@MAAWLAW) August 31, 2020

Takeda teams up with Novavax to introduce its coronavirus vaccine in Japan | @Takedapharma @Novavax @Pfizer @BioNTech @AstraZeneca @UniofOxford #Vaccines #Covid19 #Biotech #MatrixM #Maryland #OperationWarpSpeed @JNJ https://t.co/82tpoKazFb

— Aspen Biosciences (@aspenbio) August 9, 2020

Experts at @Astrazeneca, @Takeda and @Novartis tell us how to strengthen the collaboration and improve trust with patient community https://t.co/2sffvRXmJE #patients #patientcentricity #efppatients pic.twitter.com/QCW22ABoH2

— The Pharmaceutical Marketing Group (@PharmaMKTnet) September 28, 2019

Wrote about @AstraZeneca's new $1 billion plan to go carbon-zero by 2025 (carbon-neutral by 2030), and just how bad US-based big Pharma is

(Other Pharmas with near-term carbon-neutral plans: Novo Nordisk, Takeda and Novartis, all 3 EU or Japan-based)https://t.co/eqmNeLflQv

— Jason Mast (@Jasonmmast) January 23, 2020